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This thesis will focus on several rare cancers originating in the head and neck region. 
As introduction to the research described in this thesis, rare cancers in general and the 
organisation of care and research in head and neck cancer in the Netherlands will be discussed 
first.
Rare cancers 
According to the definition of Surveillance of Rare Cancers in Europe (RARECARE) rare cancers 
are characterized by an incidence of less than 6 patients per 100,000 people per year. Although 
the absolute number of patients with a specific type of rare cancer may be low, all rare cancers 
combined comprise 20 – 25 % of the total cancer incidence. Moreover, as the cancer incidence 
rises because of the ageing population, the absolute number of rare cancers will increase as 
well. 
Patients with rare cancers face specific issues; one of those is a long diagnostic pathway. 
First, the diagnosis may be delayed by a prolonged time to presentation and referral, due 
to unfamiliarity with a rare cancer in the context of certain symptoms and signs, known as 
“patients and doctors delay”. Second, the pathological diagnosis may be delayed or wrong 
due to a lack of expertise in a specific rare cancer. In sarcomas this phenomenon is well-
known and occurs in about a third of the cases (1). In salivary gland cancers a similar pattern 
is seen with 35% of specimens getting an alternative diagnosis after expert pathology review 
(preliminary own data). Finally, optimal treatment requires expertise, which is, as a matter of 
fact, not available in all hospitals for every single rare malignancy. Patients increasingly ask 
for treatment in centres of expertise and, as a consequence, there is an increasing demand for 
specialised centres and networks for diagnosis and treatment of rare tumours.
From the researcher’s’ perspective, it is much harder to get tumour material and clinical data 
from rare cancers than from common cancers, which is also the case for in vivo models for 
preclinical research. Furthermore, there is a lack of clinical trials as pharmaceutical companies 
are much less interested in these small patient populations, as the financial cost-benefit is 
often felt unprofitable. The story of imatinib in gastrointestinal stromal tumours (GIST), which 
has turned out to be a blockbuster in sarcoma, is extraordinary and its success is mainly based 
on its unique mode of action and activity in GIST patients.
Finally, less academic researchers work on rare cancers. Together, these factors contribute to 
the lack of discoveries of new treatment options for rare cancers, which leads to an increasing 
gap in overall survival of patients with a rare cancer compared to those with a common cancer. 
Data from the Netherlands Cancer Registry recently showed that the overall survival of patients 
with rare cancers hardly improved, i.e., an increase of 5-year overall survival from 50% to 56%, 
over the last 20 years (1995 to 2016). In the same time period, the overall survival of patients 
CHAPTER 1
12
with common cancers increased from 59% to 72% (2). The difference of the 5-year overall 
survival between these groups increased from 9% to 16% in this period. 
Head and neck cancer
Each year, approximately 3000 new patients are diagnosed with head and neck cancer in 
the Netherlands. The crude incidence for all head and neck cancers is approximately 18 per 
100.000 persons per year in the Netherlands. The majority of patients with head and neck 
cancer have squamous cell carcinoma of either the oral cavity, pharynx or larynx, with an 
incidence of 5 per 100.000, 5 per 100.000 and 4 per 100.000 persons per year, respectively (3). 
Risk factors for the development of squamous cell carcinomas are alcohol consumption and 
tobacco use. Furthermore,  the Human Papilloma Virus (HPV) is implicated in the pathogenesis 
of at least part of the oropharyngeal carcinomas and the Epstein Barr Virus (EBV) is recognized 
as causative agent for nasopharyngeal cancer. Other external, and currently not fully known, 
factors may also contribute to its carcinogenesis, as nasopharyngeal cancer is a relatively rare 
malignancy in most parts of the world, but it is one of the most common cancers occurring in 
China. 
Salivary gland cancers comprise a heterogeneous group of 24 different carcinomas affecting 
major and minor salivary glands (4). In the Netherlands, the crude incidence for salivary gland 
cancers is approximately 1 per 100.000 persons per year (3). For salivary gland cancers, there 
does not seem to be a correlation with the (excessive) use of tobacco and alcohol. However, 
data suggest that there is a relation between radiation exposure and the development of 
salivary gland cancers (5). Furthermore, some reports identify environmental or occupational 
exposure to toxic substances such as in the rubber manufacturing process as risk factor for 
the development of salivary gland cancers (6, 7).
In the Netherlands, patients with head and neck cancers are treated within one of the eight 
specialized head and neck oncology centres (HNOC). Seven of these centres are localized 
in academic hospitals; the remaining centre is part of the Netherlands Cancer Institute in 
Amsterdam. The HNOCs work together with their preferred partners (PP HNO) and are united 
in the Dutch Head and Neck Society (DHNS). A preferred partner is a satellite centre where 
patients with head and neck cancers may also be treated in collaboration with one of the eight 
HNOCs. The Dutch Head and Neck Society (DHNS) was established in 1984 with the aim to 
improve and excel in the care for patients with head and neck cancers. The DHNS is involved in 
the centralization of care for head and neck cancer patients. Furthermore, the DHNS performs 
multicentre studies, is involved in the development of guidelines and audits, registrations and 
recertification trainings. 
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Each HNOC has a multidisciplinary team of physicians including otorhinolaryngologists, 
oral and maxillofacial surgeons, medical oncologists, radiation oncologists, pathologists, 
radiologists and nuclear medicine specialists. Furthermore, other health care providers, 
such as clinical nurse specialists, physiotherapists, dieticians, dental hygienists, dentists and 
maxillofacial prosthetists, speech therapists, psychosocial care professionals, plastic surgeons 
and dermatologists are involved in patient care for patients with head and neck cancer. 
Organisation of multidisciplinary care in oncology in the Netherlands
The ‘stichting oncologische samenwerking’ (SONCOS) is a professional organisation, which 
was originally established between the Dutch societies for Surgical Oncology, Radiotherapy and 
Oncology, and Medical Oncology with the aim to organise multidisciplinary oncological care in 
the Netherlands to achieve the best possible care and outcome for patients. Nowadays, many 
other professional medical societies are actively involved in SONCOS. Every year, SONCOS 
publishes an updated standardisation report, describing the organisation of multidisciplinary 
cancer care in the Netherlands. Strong recommendations for care for cancer patients are 
made for each tumour type, including head and neck cancer. These recommendations include 
the number of patients each hospital should diagnose/treat every year to fulfil the minimum 
requirements and guarantee a high level of quality of care. 
The organization of treatment of head and neck patients in HNOCs is in line with these 
recommendations which entails that each HNOC should treat at least 200 new patients with 
head and neck cancers yearly to fulfil the requirements. A PP HNO should at least treat 80 new 
patients each year (8). 
Organisation of tissue collection in the Netherlands
In the Netherlands a code of conduct exists for handling of pathological tissue and slides 
obtained during routine patient care and their use for scientific purposes (‘Human Tissue and 
Medical research: code of conduct for responsible use (2011)’ rules for using pathological 
tissue and slides for scientific purposes’) (9). This code of conduct describes guidelines that 
researchers have to adhere to when making use of available material and ensures patients’ 
privacy protection. Scientific research with patient materials should be handled in a coded-
anonymous manner. 
The nationwide network and registry of histology and cytopathology (PALGA) plays an important 
role in the use of pathological tissue and slides for scientific purposes. All pathology laboratories 
in the Netherlands are connected through the PALGA network since 1971. The goal of PALGA 
is to promote the communication and data sharing within and between pathology laboratories. 
PALGA contains all results of diagnostic pathology procedures: both benign and malignant 
conditions, and also normal results (in particular from national cancer screening programs). 
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Thanks to the PALGA-network, tissues of all rare cancers are available. In an ‘intermediary 
procedure’ PALGA provides coding of patients in the database, in a way that patient data and 
pathology samples may be correlated in a coded-anonymous manner. The role of PALGA 
is unique and enables use of pathology data of Dutch pathology laboratories for scientific 
purposes in a quick, effective and cheap way. 
The collaboration with both PALGA and the Dutch Head and Neck Society is essential in the 
work that will be presented in this thesis concerning rare cancers of the head and neck. 
Rare cancers of the head and neck
Rare cancers of the head and neck encompass, among many other tumours, bone sarcomas 
and salivary gland cancers. 
As knowledge about these rare malignancies is limited, with the research described in this 
thesis I aim to provide better insight in diagnosis, clinical outcome, prognostic factors and 
treatment of afore mentioned rare malignancies of the head and neck.  
The first two parts of this thesis focus on salivary gland cancers, the third part highlights 
osteosarcomas of the head and neck (OSHN). 
PART I – salivary duct carcinoma 
The annual number of new patients with salivary gland cancer in the Netherlands is 140 to 170 
(crude incidence of salivary gland cancer approximately 1 per 100.000 persons per year)(3). 
As mentioned above, according to the current WHO classification, more than twenty different 
subtypes of malignant epithelial tumours exist in the salivary glands(4). Each subtype of 
salivary gland cancer has its distinct morphological features and clinical course. One of the 
most aggressive subtypes is salivary duct carcinoma (SDC), accounting for an estimated 5 
– 15% of salivary gland cancers. SDC is characterised by its distinct morphological features 
resembling ductal carcinoma of the breast, with comedo type necrosis and roman bridging, 
and the presence of the androgen receptor (AR). The human epidermal growth factor receptor 
2 (HER2) receptor is reported in roughly 20 – 40 % of cases. Its clinical course is characterized 
by a high rate of distant metastasis and a limited median overall survival of approximately 3 
years from presentation.
Many unanswered questions about the biology, optimal treatment and course of the disease 
exist for SDC. Due to the rarity of the tumour, only relatively small cohorts have been described, 
and those generally lack pathological review and critical information regarding the course of 
disease or applied treatments. 
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The aim of the first part of my research in SDC is to investigate the clinical outcome and 
prognostic factors of SDC patients, based on a cohort study in the Netherlands. Furthermore, 
I will study AR and HER2 expression and the activity of androgen deprivation treatment (ADT) 
and HER2 directed treatment in SDC patients. In chapter 2, a nation-wide search of SDC will 
be performed, using PALGA. With help of this PALGA nationwide search and in collaboration 
with the other HNOCs, clinical data about the diagnosis, treatment, outcome and prognostic 
factors of patients with SDC will be collected. Pathological review of all studied samples will 
be performed, to ensure the right diagnosis. As for AR and HER2 expression, we will collect 
formalin-fixed paraffin embedded tissue blocks to assemble tissue micro-arrays. Next, AR 
and HER2 expression (immunohistochemistry and FISH) will be tested on the primary tumour 
samples and correlated to clinical outcomes. In chapter 3, I will focus on patients with SDC with 
locally advanced or metastatic SDC for whom, so far, no standard treatments exist. Because 
of the presence of the AR, patients may be treated with ADT as an analogue to treatment of 
AR positive prostate cancer. In 2011, our group published the results of the treatment of 10 
patients with AR positive SDC and ADT (10). As prospective randomised studies are difficult to 
perform in SDC, reliable data on the effect of ADT are lacking. I will perform a retrospective 
study in SDC patients in the HNOCs treated over the period 1990 until 2014. Although not ideal, 
and prone to bias, I will attempt to get the most reliable data on the effect of ADT in this rare 
tumour.
I will report on the outcomes of incurable locally advanced or metastatic SDC patients treated 
with first line ADT and compare them with patients with locally advanced or metastatic SDC 
treated with best supportive care (BSC), using comparable patients from the PALGA search. 
A subset of SDC expresses the HER2 receptor. Analogous to treatment of HER2-positive breast 
cancer, some SDC patients have been treated with a combination of chemotherapy and HER2 
targeted therapy. In HER2 positive metastatic breast cancer, the addition of pertuzumab, a 
recombinant humanized monoclonal antibody directed at the HER2 dimerization domain, to 
first line treatment with docetaxel and trastuzumab increased the progression free survival 
(PFS) with 6.3 months and overall survival (OS) by 15.7 months (11). Therefore, we hypothesize 
that patients with HER2 positive metastatic SDC may also benefit from the docetaxel – 
trastuzumab – pertuzumab regimen. In chapter 4 we will describe the effect of the treatment 
of two patients with dual HER2 blockade with docetaxel, trastuzumab and pertuzumab. 
PART II – (mammary analogue) secretory carcinoma 
In 2010, a new subtype of salivary gland cancer has emerged, the mammary analogue 
secretory carcinoma (MASC). MASC resembles morphologically secretory carcinoma of the 
breast, hence the proposed name mammary analogue secretory carcinoma. However, in 2017, 
the nomenclature has changed to just ‘secretory carcinoma’ (SC), to standardize between 
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different organ sites (12). This newly defined subtype is a good example of the progress made 
in understanding molecular profiles leading to further improvement in the classification of 
salivary gland tumours.
An important characteristic of SC is the presence of the ETV6-NTRK3 fusion gene. This fusion 
gene discriminates SC from its most important differential diagnosis, namely acinic cell 
carcinoma (AciCC) and (low-grade) polymorphous adenocarcinoma of salivary glands.  
In salivary gland cancers, the ETV6-NTRK3 is only present in SC, but the ETV6-NTRK3 fusion 
is also known in other malignancies outside the salivary gland, such as secretory breast 
carcinoma and papillary thyroid carcinoma(13, 14). Although many papers have reported on 
diagnostic markers distinguishing SC from other salivary gland cancers, there are only limited 
data on the clinical course of the disease. In chapter 5 I will present clinical data from patients 
with SC and describe the clinical course and survival of these patients. Patients will be selected 
based on their morphological features and the presence of the ETV6-NTRK3 fusion gene from 
four HNOCs. We will also highlight the role of adjuvant radiotherapy.  
PART III – osteosarcoma of the head and neck 
Sarcomas are malignant mesenchymal tumours of the soft tissue and bones. In the 
Netherlands, approximately 40 – 60 patients develop an osteosarcoma each year. Most 
tumours occur in the long bones, such as the femur and the humerus. OSHN are estimated to 
comprise 5 – 10 % of all osteosarcomas and are known to develop lymphogenic metastases. 
OSHN differs in multiple ways from osteosarcomas of the extremities. Patients with OSHN 
are generally older than patients with osteosarcomas of the extremities. In contrast to 
patients with osteosarcomas of the extremities, where radical surgery can almost always 
be achieved, wide excision is usually more difficult to achieve for patients with OSHN due 
to the presence of vital structures in the head and neck region. Therefore, as the prognosis 
of patients with osteosarcomas of the extremities has historically been affected by the 
occurrence of distant metastasis, patients with OSHN face higher rates of local recurrences. 
For osteosarcomas of the extremities, it has long been recognized that the introduction of 
(neo-) adjuvant chemotherapy significantly improved overall survival due to the early treatment 
of micro - metastases. As OSHN patients have less distant metastases in comparison to 
osteosarcomas of the extremities, the use of chemotherapy in OSHN is controversial and an 
ongoing matter of debate. A systematic review of 201 patients showed a significant survival 
benefit (both OS and DFS) for OSHN patients when treated with (neo-) adjuvant chemotherapy 
(15). A meta analysis of 173 patients showed that patients with surgery alone had significantly 
longer survival rates than patients treated with surgery and adjuvant therapy (16). However, 
in this paper, critical information about resection margins was not available and may have 
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influenced results. Prospective studies to answer this question have never been done, and 
because of the rarity of the tumour  – most likely – will never be performed. Therefore, the 
best way to get insight into the added value of (neo) adjuvant chemotherapy is to collect, ideally 
prospectively, samples from a homogeneous series of patients. As building a prospective series 
will take many years, we decided to study a retrospective series of OSHN patients treated in the 
eight designated HNOCs of the DHNS. One of the main aims of this study is the comparison 
of outcome data of patients treated with (neo-) adjuvant chemotherapy with patients who did 
not receive (neo-) adjuvant chemotherapy treatment. In chapter 6 I will describe the clinical 
outcome and prognostic factors of patients with OSHN and I will specifically focus on outcomes 
of patients treated with or without (neo-) adjuvant chemotherapy.
In chapter 7 I will summarise and discuss the results of this thesis and give my future 
perspectives on the topics of this thesis.
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CHAPTER 2
A clinicopathological study and prognostic factor analysis 
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ABSTRACT
Salivary duct carcinoma (SDC) is a subtype of salivary gland cancer with a dismal prognosis 
and a need for better prognostication and novel treatments. The aim of this national cohort 
study was to investigate clinical outcome, prognostic factors, androgen receptor (AR) and 
human epidermal growth factor receptor 2 (HER2) expression. SDC patients diagnosed 
between 1990 and 2014 were identified by the Nationwide Network and Registry of Histo- and 
Cytopathology in the Netherlands (PALGA). Subsequently, medical records were evaluated 
and pathological diagnoses reviewed. Data were analyzed for overall survival (OS), disease-
free survival (DFS), distant metastasis-free survival (DMFS) and prognostic factors. AR was 
evaluated by immunohistochemistry (IHC), HER2 by IHC and fluorescent in-situ hybridization. A 
total of 177 patients were included. The median age was 65 years, 75% were male. At diagnosis, 
68% presented with lymph node metastases and 6% with distant metastases. Median OS, DFS 
and DMFS were 51, 23 and 26 months, respectively. In patients presenting without distant 
metastases, the absolute number of positive lymph nodes was associated with poor OS and 
DMFS in a multivariable analysis. AR and HER2 were positive in 161/168 (96%) and 44/153 
(29%) tumors, respectively, and were not prognostic factors. SDC has a dismal prognosis with 
primary lymph node involvement in the majority of patients. The absolute number of lymph node 
metastases was found to be the only prognostic factor for DMFS and OS. AR expression and—
to a lesser extent—HER2 expression hold promise for systemic treatment in the metastatic and 
eventually adjuvant setting.
What’s new?
Salivary duct carcinoma (SDC) is a rare and often fatal malignancy. Little is known 
about associations between its pathological features and clinical outcome. In this study, 
clinicopathological factors were analyzed for 177 patients diagnosed with SDC in The 
Netherlands between 1990 and 2014. The data show that median overall survival (OS) and 
distant metastasis-free survival (DMFS) were 51 and 26 months, respectively. At diagnosis, 
68% of patients presented with lymph node metastases.
Lymph node positivity was associated with poor OS and poor DMFS. The absolute number of 
metastatic lymph nodes was the only significant prognostic factor for survival in a multivariate 
analysis. Androgen receptor and human epidermal growth factor 2 (HER2) were positive in 96% 
and 29%, respectively and were not a prognostic factor.
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INTRODUCTION
Salivary duct carcinoma (SDC) is a rare subtype of salivary gland cancer (SGC). It was first 
described in 1968(1), and defined as a distinctive entity in 1990(2). SDC usually affects middle-
aged men and the tumor is often located in the parotid gland. Patients frequently present with 
locally advanced disease. Primary treatment consists of resection of the primary tumor and 
neck dissection, usually followed by radiotherapy. SDC is characterized by a high rate of distant 
metastases resulting in a limited overall survival (OS)(3). 
Immunohistochemically, SDC resembles prostate cancer, because of common expression of 
the androgen receptor (AR)(4). Androgen deprivation therapy (ADT) in a small series showed a 
50% clinical benefit rate with a median duration of 12 months(5). Morphologically, SDC shows 
similarities with invasive ductal carcinoma of the breast. However, SDC only rarely shows 
estrogen and progesterone receptor expression.
Expression of the Human Epidermal Growth Factor Receptor 2 (HER2) was reported in 44% of 
32 patients with SDCs(6).
Due to the rarity of disease, only relatively small cohorts have been described and prognostic 
factors remain to be elucidated. The largest studies with 495 SDC patients based on the National 
Cancer Database (NCDB) and with 228 SDC patients based on the Surveillance, Epidemiology, 
and End Results Program (SEER) database, lack vital information on the occurrence of local 
and regional recurrences, distant metastases, the use of systemic therapy, and AR or HER2 
expression(3). Furthermore, no pathologic review was performed in both studies.
Thanks to the unique collaboration between the Dutch Pathology Network PALGA and the 
national network of head and neck centers, we collected data of patients diagnosed with SDC 
in the Netherlands and aimed to evaluate clinicopathological characteristics (such as AR and 
HER2 expression and primary treatment) in relation to clinical outcome and prognostic factors.
PATIENTS AND METHODS 
Patient selection
Patients diagnosed with SDC between 1990 and 2014 were identified by means of a retrospective 
search by the Nationwide Network and Registry of Histo- and Cytopathology in the Netherlands 
(PALGA)(7). As all Dutch pathology laboratories participate in this network, all patients with a 
registered diagnosis of SDC in the Netherlands were enrolled. All patients were coded by PALGA 
and clinical data could be correlated with the pathological features in a coded procedure. 
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Clinical data
Clinical data were collected from the medical records and were obtained with permission of 
treating physicians according to Dutch national laws and Good Clinical Practice. Review by a 
medical ethical committee was not obligatory by Dutch law due to the retrospective nature of 
the observations. 
Pathology
For all patients, hematoxylin and eosin (H&E) stained slides, formalin fixed paraffin embedded 
(FFPE) tumor blocks and corresponding anonymous pathological reports were requested. All 
patient materials used in this study were obtained during routine patient care, and used for 
scientific research with permission by Dutch Law (‘Code for Secondary Use of Human Tissue’, 
Dutch Federation of Medical Scientific Societies). H&E slides were used for re-evaluation of 
the diagnosis and to mark areas of primary tumor by an experienced pathologist (UF). From 
each “donor” block one to three cores of primary tumor were transferred into the “recipient” 
tissue micro array (TMA) block, using the TMA Grandmaster by Sysmex. From the new TMA 
“recipient blocks” slides were produced for further analysis. Each TMA slide was analyzed for 
AR and HER2 and scored by the pathologist (UF), who was blinded for the clinical outcome. 
AR (immunohistochemistry (IHC)) and HER2 (either IHC or fluorescent-in-situ-hybridization 
(FISH)) acquired during routine clinical care procedures was permitted in case it was not 
possible to determine AR or HER2 with a TMA. In case of heterogeneity between cores or 
between TMA and clinically obtained results, the highest score was used.
For AR expression, the AR polyclonal antibody of Santa Cruz was used, dilution 1:200, 
pretreatment with citrate (pH 6.0) for 10 minutes in a pretreatment module (Labvision/
thermo scientific by Klinipath/VWR). Then, immunostaining was carried out with the detection 
system (Brightvision) of Immunologic, Duiven, the Netherlands. AR immunhistochemistry was 
executed in the Radboudumc. AR was scored positive or negative based on diffuse nuclear 
staining, as described in the WHO classification of SDC(8).
HER2 was determined upfront by both IHC and FISH. The Hercepkit of DAKO was used according 
to protocol for HER2 immunostaining. For HER2 FISH, the probe of Kreatech (location of 
hybridization on 17q12cep17) was used. The probe was incubated according to standard ISH 
protocol. Scoring of HER2 was performed according to guidelines from the American Society 
of Clinical Oncology (ASCO) and College of American Pathologists (CAP) analogous to breast 
cancer(9). HER2 IHC and FISH were scored independently. After scoring IHC and FISH, the 
results were compared. As the guideline does not mention how to report on discrepancies 
between IHC and FISH, we considered the result of HER2 FISH directive in discordant cases, 
i.e. HER2 IHC3+ and HER2 FISH negative was scored as HER2 negative. 
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Definitions and statistical analysis
Lymph node ratio (LNR) was defined as the number of tumor positive lymph nodes divided by 
the total number of lymph nodes resected. Date of diagnosis was defined as date of obtaining 
the first histological proof of SDC.  In case the diagnosis was confirmed in a later stadium, the 
original date of obtaining the histopathological material was used. Overall survival (OS) was 
measured from date of diagnosis until death of any cause. Patients alive at last known follow up 
date were censored. Disease free survival (DFS) was measured from date of surgery until date 
of local or regional recurrence, distant metastases or death of any cause, whichever came first. 
Patients alive without disease at last known follow up were censored. Distant metastasis free 
survival (DMFS) was defined as date of diagnosis until date of distant metastases or death of any 
cause, whatever came first. Patients alive without distant metastasis were censored. Survival 
curves were estimated with the Kaplan-Meier method. To investigate association between 
patient and tumor characteristics and survival, univariate Cox proportional hazards regression 
models were fitted first. Next, a multivariable Cox regression model was estimated with a 
forward selection procedure based on the Wald test at significance level 0.05. The variables 
used in the multivariable analysis for OS and DMFS included gender, age (categorical), T- and 
N-stage, number of positive lymph nodes (categorical), AR, HER2, carcinoma ex pleomorphic 
adenoma, primary tumor site and resection margins. Patients with metastatic disease at 
diagnosis and patients with missing values in one or more of the variables were excluded from 
the multivariable analysis. Data were analyzed using SPSS version 22.0.
RESULTS
Patient and tumor characteristics 
Pathological review led to the inclusion of 177 eligible SDC patients out of 294 patients in the 
PALGA database (Figure 1). Patient characteristics are shown in Table 1. The median age was 65 
years [range 38–92], and the majority was male (75%). The parotid gland was the most affected 
(82%) salivary gland. Thirty-six percent of patients had an SDC arising from a pleomorphic 
adenoma (carcinoma ex pleomorphic adenoma). One-hundred and twenty patients (68%) had 
lymph node metastases. Eleven patients (6%) presented with distant metastases. Ninety-six 
percent of 168 evaluable tumors were AR positive. Twenty-nine percent of the 153 evaluable 
tumors were HER2 positive. One-hundred and forty patients were evaluated for AR and HER2 by 
using the TMA, the scores of the remaining patients were based on routine clinical evaluations. 
Table 2 shows the number of patients evaluated by FISH and IHC. Four patients had HER2 
IHC3+ but had a negative HER2 FISH, and were scored as HER-2 negative. 
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Figure 1. Consort diagram of inclusion of SDC patients. PALGA is the Nationwide Network and Registry 
of Histo- and Cytopathology in the Netherlands.
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Table 1. Patient’s and tumor characteristics 
Characteristics Number of patients 
(n = 177) 
Median age, in years
    Range, in years 
Age, in years, n (%)
    ≤ 50 
    51 – 60 
    61 – 70 
    71 – 80
    > 80 
65 
38 – 92 
19 (11)
43 (24)
54 (31)
41 (23)
20 (11)
Gender, n (%) 
    Male 
    Female 
133 (75)
44 (25)
Primary tumor, n (%)
    Parotid gland
    Submandibular gland 
    Sublingual gland 
    Other 
            Minor salivary glands
            Lacrimal gland1  
            Unknown     
145 (82)
19 (11)
2 (1)
7 (4)
1 (1)
3 (2)
Presenting symptoms, n (%)
    Painless mass 
    Painfull mass 
    Facial nerve paralysis 
    Unknown
84 (48)
27 (15)
51 (29)
15 (9) 
Carcinoma ex pleimorphic adenoma, n(%) 
    Yes 
    No (“de novo”)   
63 (36)
114 (64)
TNM stadium
    T1/T2/T3/T4/Tx
    (%)
    N0/N1/N2/N3
    (%)
    M0/M1
    (%)
29/49/20/68/11
(16/28/11/38/6)
57/15/104/1
(32/8/59/1)
166/11
(94/6)
Overall stage 
     I/II/III/IV/unknown
     (%)
16/18/10/130/3
(9/10/5/73/2)
Primary treatment with curative intent2 ( n = 162)
Surgery, n (%)
     Resection primary tumor with neck dissection
     Resection primary tumor without neck dissection
     Neck dissection only   
Postoperative radiotherapy, n (%) 
     Yes
     No   
123 (76)
36 (22)
3 (2)
149 (91)
13 (9)
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Table 1. continued
Neck dissection3
     Median number of resected lymph nodes, range 
     Median number of positive lymph nodes, range 
     Median lymph node ratio, range
27 ( 1 – 122) 
4 ( 0 – 97) 
0.20 [0 – 1.00]
Androgen receptor (AR), n (%)4 
     Positive 
     Negative 
162 (96)
6 (4)
HER2, n (%)5
     Positive    
     Negative 
HER2 determination methods, n (%)
     FISH and IHC 
     FISH     
     IHC 
45 (29)
108 (71)
140 (92)
5 (3)
8 (5)
1 Histopathological appearance of SDC despite its localisation in the lacrimal gland.
2 one patient underwent primary surgery despite distant metastases on baseline imaging in retrospect.
3 n = 126 patients.
4 Nine patients had no AR result. n = 168 patients.
5 Twenty-four patients had no HER2 result. n = 153 patients. 
Primary treatment with curative intent
Of the 177 patients, 162 patients underwent primary surgery with curative intent. 
Fourteen patients did not have surgery because of an irresectable tumor in 3 patients or distant 
metastases at diagnosis in 11 patients. One patient underwent primary surgery of the primary 
tumor and neck dissection, but in retrospect had distant metastases on baseline imaging, and 
was not considered as having been treated with curative intent. 
Surgery
One hundred and sixty-two patients had primary surgery, of which 123 patients had a resection 
of the primary tumor and neck dissection, 36 patients only had a resection of the primary tumor. 
Three patients only underwent a neck dissection, because no primary tumor could be detected. 
In patients who underwent a neck dissection (n=126) , the median number of tumor positive 
lymph nodes was 4 [range 0–97](table 1). Figure 2 shows the number of tumor positive lymph 
nodes plotted against the total number of lymph nodes examined in the resected specimens 
(number of patients = 126). The median LNR was 0.20.
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Radiotherapy
One hundred and forty-nine of 162 patients (91%) received postoperative radiotherapy. The 
median dose was 66 Gy (range 14 – 70 Gy). Only one of these patients underwent adjuvant 
concurrent chemoradiotherapy (CRT) (radiotherapy combined with weekly Cisplatin).
Figure 2. Tumor-positive lymph nodes are plotted against the total number of lymph nodes during neck 
dissection  (number of patients = 126). The dark blue line represents the line at which all resected lymph 
nodes would have been tumor positive. 
Patterns of recurrences and distant metastases 
Eighty-seven out of 162 patients (54%) developed locoregional recurrence and/or distant 
metastases after primary treatment with curative intent. Figure 3a shows the Venn diagram 
of local, regional and distant recurrences in 162 patients treated with curative intent. Eighty-
four out of 177 patients (47%) had distant metastases during the course of disease; 11 (6%) 
patients had distant metastatic disease at diagnosis, and 73/162 (45%) patients developed 
distant metastases after primary treatment with curative intent. Figure 3b shows the sites of 
distant metastases for 84 patients who had distant metastases at diagnosis (n=11) or developed 
distant metastases after treatment with curative intent (n=73). Pulmonary (54%), bone (46%) 
and lymph nodes (42%) metastases were most frequently encountered. Brain metastases 
occurred in 15 (18%) patients. Of these 15 patients with brain metastases, the HER2 status was 
available in 13. Five out of 13 patients (38%) were HER2 positive, the other 8 patients (62%) were 
HER2 negative. The median time until the occurrence of distant metastases was 16 months 
(range 1–69 months). 
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a)
b)
Figure 3. Patterns of disease recurrence 
(a)  Breakdown of local and regional recurrences and distant metastases in 87 patients with a recurrence. 
The numbers in the circles represent the absolute number of patients with local and regional 
recurrences and the presence of distant metastases. Patients with primarily metastatic disease are not 
included in this figure. 
(b)  Localisation of distant metastases sorted by percentage of presence in 84 patients with distant 
metastases. Patients with primarily metastatic disease were included in this figure. 
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Treatment with palliative intent 
In total, 84 patients had distant metastases (11 at time of diagnosis, 73 after treatment with 
curative intent) and three patients had unresectable disease. One of these three patients 
received primary radiotherapy. The other two patients were treated with palliative ADT. Thirty-six 
patients with distant metastatic SDC received ADT as first- or second-line palliative treatment. 
Fifteen (18%) patients underwent chemotherapy and four (5%) patients targeted therapy. Most 
regimens included either taxanes (docetaxel or paclitaxel) or platinum (cisplatin or carboplatin) 
based chemotherapy. Some patients received multiple lines of systemic therapy. Forty-four 
(54%) of 84 patients with distant metastases  received only best supportive care. A total of 39 
(46%) patients with distant metastases underwent radiotherapy with palliative intent. 
Survival 
After a median follow up of 26 months, 84 of 177 patients had died. The 5- and 10-years survival 
were estimated as 43% [95%CI 33-52%] and 26% [95%CI 15-37%], respectively. The 5- and 10-
year DFS were estimated as 28% [95%CI 20-36%] and 17% [95%CI 8-25%], respectively. The 
5- and 10 year DMFS were 32% [ 95%CI 24-40%] and 20% [95%CI 2-29%], respectively. 
Estimates for the median OS, DFS and DMFS were 51 months (95%CI 40–61 months), 23 
months (95%CI 18-27 months) and 26 months (95%CI 20-34 months), respectively. The Kaplan-
Meier curves for OS, DFS and DMFS are shown in figure 4a-4c. 
Prognostic factors 
Patient selection
All 177 patients were included in the univariate analysis. Patients with distant metastases at 
diagnosis were not included in multivariable analyses for OS and DMFS. Owing to missing 
values, only 136 patients were included in the multivariable predictive model for OS and DMFS. 
Overall survival 
Univariate analysis showed that male gender, high N-stadium, increasing number of tumor 
positive lymph nodes, LNR and primarily metastatic disease at diagnosis were associated 
with poor OS. The multivariable prediction model only contained the number of positive lymph 
nodes as independent variable: an increasing number of positive lymph nodes negatively 
affects survival (overall p=0.003)( 3–15 lymph nodes vs. 0 lymph nodes HR 2.17, 95%CI 1.09–
4.32, p=0.028 ; >15 lymph nodes vs. 0 lymph nodes HR 3.96, 95%CI 1.84–8.55, p=0.000). The 
number of lymph nodes was categorized due to a non-linear correlation with OS. 
No significant association was found between AR and HER2 and OS in the univariate as well as 
the multivariable analysis. The results of the univariate and multivariable analyses for OS are 
shown in Table 2. 
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a)
b)
c)
Figure 4. Kaplan-Meier curves for overall survival (OS), disease free survival (DFS)  and distant metastasis 
free survival (DMFS) based on data of 177 SDC patients. 
(a)  Kaplan-Meier curve for OS based on data of 177 SDC patients. Estimated median OS was 51 months 
(95% CI 40 – 61 months).
(b)  Kaplan-Meier curves for DFS based on data of 177 SDC patients. Estimated median DFS was 23 months 
(95% CI 18-27 months).
(c)  Kaplan-Meier curve of DMFS based on data of 177 SDC patients. Estimated median DMFS was 26 
months (95% CI 20 - 34 months).
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Distant metastasis free survival 
Male gender, high T-stadium, high N-stadium, increasing numbers of positive lymph nodes 
and LNR were associated with poor DMFS using univariate analysis. The final multivariable 
prediction model only contained the number of positive lymph nodes as independent variable; 
an increasing number of positive lymph nodes is a prognostic factor for poor DMFS (overall 
p=0.000)(3–15 lymph nodes vs. 0 lymph nodes HR 2.25, 95%CI 1.25–4.06, p=0.007; >15 lymph 
nodes vs. 0 lymph nodes HR 4.73, 95%CI 2.48–9.00, p=0.000). The number of lymph nodes was 
categorized due to non-linear correlation with DMFS. From the univariate and multivariable 
analysis no significant association was found between DMFS and AR and HER2. The results of 
the univariate and multivariable analysis for DMFS are displayed in Table 2. 
DISCUSSION
In this article, we present 177 patients with SDC, which represents the largest series of SDC 
patients with pathological review worldwide. These data provide extensive insight in treatment, 
clinical outcome, AR and HER2 expression/amplification and prognostic factors in SDC 
patients. This study underscores the aggressive clinical course characterized by a high rate of 
distant metastases (47%), and a median OS of 51 months. AR and HER2 were positive in 96 and 
29% respectively; both were of no prognostic value as they were not significantly associated 
with OS and DMFS. The number of positive lymph nodes was the only factor independently 
associated with poor OS and DMFS. 
SDC has a high propensity for lymph node and distant metastases; 68% of our patients presented 
with lymph node metastases, which is higher than the 46.6% and 49% reported by Osborn and 
Jayaprakesh et al(3, 10). An abundancy of tumor positive lymph nodes was observed in neck 
dissections. Furthermore, distant metastases were observed relatively short after primary 
diagnosis with a median time until distant metastases of only 16 months. Although distant 
metastases occurred mostly in the lungs, bones and lymph nodes, a wide variety of metastatic 
sites were seen, of which the 18% rate of brain metastasis was most notable. Local and regional 
recurrences were often accompanied by distant metastases. In this study 67% of patients 
with a local or regional recurrence also had distant metastases, as shown in figure 3a, which 
corresponds to the 23 –75% found in two other reports(11, 12). Therefore, in case of local or 
regional recurrences, we suggest thorough screening for distant metastases, as this may change 
treatment from curative to palliative intent. Moreover, despite locoregional control, distant 
metastases were encountered during follow-up in 42 patients. Notably, 54% of patients with 
metastatic disease did not receive any form of systemic treatment. Possible explanations for 
this may be the extensiveness of disease, performance status, co-morbidity, and unfamiliarity 
of physician with the treatment of this rare tumor type, especially during the early years of the 
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time period that we have studied. This may have influenced the overall survival of SDC patients 
in general. 
Recently, a few cohort studies on patients with SDC were published. The cohort based on the 
National Cancer Database (NCDB) is the largest cohort of SDC patients with 495 patients (no 
median OS described for all patients) followed by the SEER database with 228 patients (median 
OS 79 months)(3, 10). However, lack of pathology review has a risk of including patients with 
other diagnosis as the histological diagnosis of SDC is notoriously difficult. The median OS 
in the present study (51 months) was comparable to a cohort study of 56 patients in a single 
institution in Korea (OS of 48 months)(13). In a Japanese study with 141 SDC patients, where 
all tumors were pathologically reviewed, three-year OS was 73% versus 57% in our series(11).
In our series, 96% of tested tumors had a positive AR. This is comparable with other series 
of SDC patients reporting AR positivity up to 89%(4). AR positivity, in presence of the typical 
morphological features, is strongly suggestive for SDC, although other subtypes of SGC may 
express AR(14). ADT is an interesting therapeutic option for AR positive SDC(5). The results of 
first-line ADT in our patients will be published in a separate article(15). 
We confirmed the presence of HER2 in 29% of tested cases, which is in line with the previously 
described HER2 amplification/expression in 27% (of 41), 32% (of 31) and 44% (of 32) SDC 
cases(6, 16, 17). We reported on four patients with HER2 IHC3+ with HER2 FISH negative 
tumor samples. Although this is unusual, it is known from comparative studies that this may 
occur(18). Recently, preliminary data for 45 patients with HER2 positive advanced unresectable 
SGC (of the ductal subtype) treated with docetaxel and trastuzumab in a phase 2 trial showed 
promising results, that is, overall response rate of 69%, median PFS of 11.3 months and median 
OS of 38.0 months(19). These results seem to support treating HER2 positive SDC patients with 
trastuzumab plus docetaxel. 
Unfortunately, it was not possible to correlate clinical outcomes to other genetic alterations 
such as TP53 and PI3KCA. Future research may include characterization of genetic alterations 
and clinical outcomes of SDC patients. 
Studies demonstrated a correlation between lymph node metastases and OS. There seems to be 
no consensus on the best way of categorizing lymph node metastases, whereby classifications 
comparing N0-1 versus N2-3, N2b-c versus N0-N2a, or N0 versus any N+ disease are used(3, 
12, 13, 20). We demonstrated in the univariate analysis that lymph node metastases is indeed 
a significant prognostic factor. However, in the multivariable analysis, the absolute number of 
tumor positive lymph nodes is a stronger prognostic factor than the N-stage and LNR(21). We 
therefore suggest a categorizing system according to the absolute number of tumor positive 
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lymph nodes (categorized as 0, 1-2, 3-15 and >15 lymph nodes), although this needs to be 
validated in other SDC cohorts.
One may argue if the patient with SDC of the lacrimal gland should be included in the analysis, 
however, the histopathological features in this particular patient included comedo type 
necrosis and AR positivity. Recently, another case of AR positive SDC of the lacrimal gland was 
described in literature(22). 
The main strengths of this study are the large number of patients data collected by using a 
nationwide search strategy by PALGA, which covers 95-100% of all cancer patients, and especially 
the pathological review of SDC cases. A major advantage of our data, as compared to the larger, 
national NCDB and SEER databases, is the availability of individual patient data in our cohort. 
Extensive data on diagnosis, treatment, recurrence patterns and survival could be collected and 
has given valuable insights not only in the presentation but also in the course of the disease. 
We were therefore able to analyze meaningful prognostic factors in univariate and multivariable 
analyses. Limitations of this study are mainly due to its’ retrospective nature, the absence of 
FFPE blocks for AR and HER2 testing in some cases, and a not 100% coverage of all detailed 
information. Only tumors classified as SDC were included, therefore, patients that may have been 
wrongfully classified i.e., as another subcategory of the SGCs, may have been missed.
In conclusion, we presented 177 SDC patients with pathological review of the diagnosis. The 
median OS was just over 4 years, and the disease was characterized by a high initial lymph 
node involvement and development of a high rate of distant metastases. In the multivariable 
analysis the absolute number of positive lymph nodes was the only significant prognostic 
factor for both poor OS and DMFS. We advocate the determination of AR and HER2 as this 
may have therapeutic consequences, although these are not prognostic factors. Given the high 
recurrence rate, future clinical research could encompass adjuvant treatment in high-risk 
lymph node positive patients.
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ABSTRACT 
Background
Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen 
receptor-positive. Only limited data are available on androgen deprivation therapy (ADT). 
Methods 
Patients with advanced androgen receptor-positive SDC treated with first-line ADT were 
retrospectively evaluated for clinical benefit ( i.e., partial response [PR] and stable disease [SD], 
progression-free survival [PFS] and overall survival [OS]). The OS was compared with advanced 
SDC patients who received best supportive care.
Results 
Thirty-four out of 35 ADT-treated patients were evaluable: 6 patients had a PR (18%) and 11 
had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the 
ADT-treated patients was 4 months and the median duration of clinical benefit was 11 months. 
The median OS was 17 months versus 5 months in 43 patients receiving best supportive care 
(p=.02). 
Conclusions
We recommend ADT in advanced androgen receptor-positive salivary duct carcinoma given its 
response and clinical benefit. 
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INTRODUCTION
 
Salivary gland cancers comprise a heterogeneous group of carcinomas. Salivary duct carcinoma 
is a very aggressive subtype of salivary gland cancer with a high risk of distant metastatic 
disease. The median overall survival (OS) is approximately 3 years after primary diagnosis(1-3).
In case of distant metastatic disease, no standard treatment options are available and most of 
the treatments described in literature are based on small case series or case reports. 
Most salivary duct carcinomas express the androgen receptor (4); the percentage of androgen 
receptor positivity varies between 67 and 89%(5-7). Based on this androgen receptor expression, 
patients have been treated with androgen deprivation therapy (ADT), such as bicalutamide, an 
androgen receptor antagonist with a non-steroidal structure, similar to the treatment with ADT 
for patients with prostate cancer. Due to the rarity of the disease, a clinical study has never 
been performed. In 2011 we reported on ten patients with salivary duct carcinoma treated 
with ADT in a single center (Radboud University Medical Center), with a clinical benefit rate 
of approximately 50% and a median progression free survival (PFS) of 12 months in patients 
with clinical benefit(8). The purposes of this retrospective study are to determine the efficacy of 
ADT in a nationwide group of patients with incurable locally advanced or metastatic androgen 
receptor-positive salivary duct carcinoma patients in terms of response, duration of response, 
and median OS. In addition we aim to describe the outcome of a group of patients with 
incurable locally advanced or metastatic salivary duct carcinoma who received best supportive 
care during the same period.
PATIENTS AND METHODS
This study was performed in accordance with institutional ethical guidelines. In a retrospective 
search by the Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) 
in The Netherlands, we collected all patients diagnosed with salivary duct carcinoma in the 
time period 1990 – 2014.(9) An experienced pathologist (UF) reviewed all pathology slides 
for central confirmation of the diagnosis. This enabled us to collect data of 177 patients with 
salivary duct carcinoma. In The Netherlands, treatment of patients with head and neck cancer 
is centralized in 8 head and neck cancer centers and 6 collaborating major hospitals. Clinical 
data of all these patients, including age, gender, primary tumor site, presenting symptoms, 
pathological report (all reviewed), pathological TNM classification, expression of androgen 
receptor, development of local or locoregional recurrence or distant metastases, treatment, 
such as surgery, radiotherapy or systemic treatment, response evaluation in case of systemic 
treatment, PFS and OS, were obtained by reviewing medical records with permission of the 
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treating physicians. By Dutch law, a review by a medical ethical committee was not needed 
due to the retrospective nature of these observations. Of all 177 patients, only the 86 patients 
with distant metastatic (n=84) or incurable locally advanced salivary duct carcinoma (n=2) were 
analyzed in further detail. Patients treated with ADT as first-line palliative treatment were 
included for analysis about efficacy. Patients who received any other systemic treatment before 
ADT were excluded (chemotherapy, targeted therapy or adjuvant systemic therapy before ADT). 
Ten patients of the current series were already described in an earlier report.(8)
Androgen receptor testing
For all 177 patients with salivary duct carcinoma, efforts were made to evaluate the androgen 
receptor. In 140 patients the androgen receptor was determined using the androgen receptor 
polyclonal antibody of Santa Cruz, dilution 1:200, pretreatment with citrate (pH 6.0) for 10 
minutes in a PT module. Immunostaining was carried out with the Powervision method by 
Immunologic. The androgen receptor was scored positive or negative based on diffuse 
nuclear staining, as described in the World Health Organization classification of salivary duct 
carcinoma (10). For the remaining patients, no tumor material was available for additional 
androgen receptor staining. Therefore, the results of androgen receptor determined during 
routine clinical care procedures were used.
Treatment protocol
Patients who received ADT were treated with 150 mg bicalutamide once daily (q.d.) or a 
combination of a luteinizing hormone-releasing hormone (LHRH) analog (i.e., goserelin 3.6 mg 
subcutaneously every 4 weeks, with 50 mg bicalutamide q.d.). 
Response Evaluation
Patients were evaluated approximately every three months. Tumor evaluation was measured 
using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.(11) Clinical benefit 
was defined as: complete response (CR), partial response (PR) or stable disease. The PFS 
was defined as the time between start of ADT until documented date of progressive disease 
(PD) or death, whatever came first. The OS was counted from date of confirmation of distant 
metastasis until date of death of any cause. Patients alive at last follow up were included in the 
analysis as censored. 
Clinical outcomes of ADT-treated patients were compared with clinical outcomes for patients 
with distant metastasis or incurable locally advanced disease who received best supportive 
care. 
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Statistical analysis 
The OS was estimated by Kaplan-Meier survival curves. The log rank test was used to compare 
OS between different groups of patients. A P value of <0.05 was considered significant. 
To study the association between treatment and survival, an association Cox regression model 
was fitted to the data. First, the regression model with only treatment as independent variable 
was estimated. The hazard ratio in this model represents the association that is uncorrected for 
possible confounders (age, gender, androgen receptor status, primarily metastasized disease, 
organ involvement). Next, the model was adjusted for possible confounders by a forward 
selection procedure. In every step it was checked whether one of the possible confounders 
needed to be added to the model as independent variable additional to the variables already 
included in the model. By including it into the model, the variable that causes the biggest change 
in the association between treatment and survival (estimate of the regression coefficient), but 
at least 10%, and had a P value of, at the most, 10% (Wald-test), was selected for inclusion to 
the model. This step was repeated until no variables could be included to the model. Analyses 
were performed using SPSS version 22.0.
RESULTS 
Patient selection 
A total of 177 patients with salivary duct carcinoma were retrieved from the nationwide search. 
Eighty-six patients had incurable locally advanced (n = 2) or metastatic (n= 84) salivary duct 
carcinoma, of which 38 were treated with ADT. Of these 38 patients, 3 patients were excluded: 
2 patients received chemotherapy as first-line treatment before to ADT, and another patient 
because of prior adjuvant ADT. Forty-four patients received best supportive care, of which one 
patient was excluded because this patient received adjuvant ADT, which led to a total of 43 
patients who received best supportive care only. The other 4 patients received chemotherapy 
and/or targeted therapy only and were not included in the analysis. Figure 1 shows the flow 
chart of these patients.
Patient characteristics and treatment
The baseline characteristics of the 35 patients receiving first-line ADT and the 43 patients 
receiving best supportive care are displayed in Table 1. Patients were median 64 and 68 years of 
age, and 86% and 81% of patients were men, respectively. The percentage of the sites of distant 
metastases and the number of sites of distant metastases per patient are shown in Table 1.
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Figure 1. Flow chart of patients with salivary duct carcinoma (SDC; n = 177) and patients with incurable 
locally advanced or metastatic salivary duct carcinoma(n = 86). Patients treated with first-line androgen 
deprivation therapy (ADT) and patients receiving best supportive care (BSC) are shown. Text boxes in 
cursive represent excluded patients.
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Table 1. Baseline characteristics of patients with incurable locally advanced or metastatic salivary duct 
carcinoma patients. 
ADT 
No. of patients = 35
BSC
No. of patients  = 43
Median age, years, range 64 (38 – 83) 68 (42 – 84)
Sex, no. of patients (%)
   Male 
   Female 
30 (86) 
5 (14) 
35 (81)
8  (19)
Androgen receptor expression, no. of patients (%)
    Positive 
    Negative
    Not performed 
35 (100)
0
0
35 (81) 
2 (5) 
6 (17)
Distant metastasis, no. of patients (%)
    Presenting with distant metastases
    Sequential presentation of distant metastases
10 (29)
23 (66)
1 (2)
42 (98) 
Median time between diagnosis and                                                     
metastases, months (range)
15 (1 – 69) 14 (1 – 46)
Sites of distant metastasis, no. of patients (%)
   Lungs 
   Bones
   Lymph nodes
   Liver 
   Brain 
   Other 
20 (57)
19 (54) 
22 (63)
7 (20)
3 (9)
5 (14)
19 (44)
16 (63)
8 (19)
12 (28)
8 (19)
5 (12)
No. of involved organs per patient, no. of patients (%)
    0 involved organs 
    1 involved organs
    2 involved organs
    3 involved organs
    4 involved organs
    5 involved organs
2 (6)
12 (34)
6 (17)
10 (29)
3 (9)
2 (6)
0 (0)
26 (61)
11 (26)
4 (9)
2 (5)
0 (0) 
Abbreviation: ADT, androgen deprivation therapy; BSC, best supportive care. Patients receiving ADT and 
best supportive care (BSC) are mentioned separately.
Androgen receptor status was determined using the polyclonal androgen receptor 
antibody from Santa Cruz in 17 of 35 ADT-treated patients and 33 of 43 best supportive 
care-treated patients. For the remaining patients, no tumor material was available for 
additional androgen receptor staining. Therefore, the results of androgen receptor as 
determined during routine clinical care were used. In 6 best supportive care-treated 
patients, the androgen receptor expression was not determined and, therefore, unknown. 
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Of the ADT-treated patients, twenty-eight patients (80%) received single-agent bicalutamide, 
whereas 7 patients (20%) received an LHRH analogue in combination with low-dose 
bicalutamide.
Although ADT was usually well tolerated, 1 patient switched to another form of ADT and 2 male 
patients (6%) stopped because of presumed toxicity (ie, fatigue and loss of appetite).
Response to androgen deprivation therapy and survival  
Of the 35 ADT-treated patients, 1 patient requested to discontinue treatment before the first 
evaluation and was left out of the response evaluations. Six out of 34 evaluable patients (18%) 
had a PR, 11 (32%) had stable disease, and 17 (50%) had PD (Table 2). All patients with a PR 
were treated with bicalutamide monotherapy. Figure 2 shows the CT imaging at baseline and 
after 15 months of ADT in a patient with PR. In total, 50% had clinical benefit and stayed on 
treatment for a median duration of 11 months (95% confidence interval [CI] 6 – 15 months). 
Median PFS for all ADT-treated patients was 4 months (95% CI 3 – 5 months; Table 2). At the 
time of analysis, 6 patients were still on first line ADT. 
Table 2. Response evaluation, progression free survival and overall survival of androgen deprivation 
therapy-treated patients. 
ADT
No. of patients = 35a
BSC
No. of patients = 43
Response evaluation, no. of patients (%) 
PR 
Stable disease  
PD 
Not evaluable  
6 (18) 
11 (32) 
17 (50)
1
Median PFS in months [95% CI]
Median PFS in patients with PR or stable disease  
in months [95% CI]
4 [ 3 – 5 ]
11 [ 6 – 15 ]
Median OS in months [95% CI] 17 [ 10 – 24 ]  5 [ 1 – 9 ]
Abbreviations: ADT, androgen deprivation therapy; BSC, best supportive care; CI, confidence interval; OS, 
overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response.
The OS for best supportive care patients is also shown. 
aThere were 34 evaluable patients.
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Figure 2. One of the 6 patients with a partial response on androgen deprivation therapy (ADT). Baseline CT 
imaging of mediastinal lymph nodes (left) and after 15 months of ADT (right). The patient was treated with 
bicalutamide alone. 
The median follow up time was 10 months (range 1 – 64 months). The median OS for ADT-
treated patients was 17 months (95% CI 10 – 24 months). The median OS for the ADT-treated 
patients with clinical benefit was 29 months (95% CI 8 – 51 months) and for patients with PD 
this was 8 months (95% CI 5 – 10 months; Table 2). Two of 5 female patients had a PR on ADT. 
Possibly since the numbers are small, we did not observe significant differences in OS or PFS 
between male and female patients treated with ADT, nor did we observe a significant difference 
between patients treated with single-agent bicalutamide or LHRH analogs with bicalutamide. 
The median OS for patients treated with best supportive care was 5 months (95% CI 1 – 9 
months; Table 2). The association between treatment and survival was investigated by 
means of estimating a Cox regression model. No confounders were found. The estimated 
survival curve for ADT treated patients in a Cox regression model is shown in Figure 3. 
The ADT-treated patients had a significantly better OS than best supportive care 
patients in this Cox regression model (p = .024; hazard ratio 0.53; 95% CI 0.30 – 0.92). 
Consecutive systemic treatments 
After PD on ADT as first-line treatment, 11 patients received second-line ADT. Depending on 
the agents the patients received as first line, patients were treated with an LHRH analog, either 
as mono therapy, or combined with bicalutamide and/or a 5-alfa-reductase-inhibitor. Of the 
10 patients treated with first-line bicalutamide monotherapy 2 patients were consecutively 
treated with an LHRH analog, 7 patients with an LHRH analog in combination with low-dose 
bicalutamide (50 mg), and 1 patient with a combination of an LHRH analog, bicalutamide, and 
5-alfa-reductase-inhibitor. One patient treated with an LHRH analog in combination with low-
dose bicalutamide in first-line, was treated in second-line with an LHRH analog. 
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Figure 3. Cox regression survival curves for all androgen deprivation therapy (ADT)-treated versus best 
supportive care (BSC) patients. The ADT-treated patients had significantly better overall survival compared 
to patients receiving best supportive care (p = .024; hazard ratio 0.53; 95% confidence interval 0.30 – 0.92).
Six patients had stable disease for a median of 9 months (95% CI 6 – 12 months), 4 patients 
had PD and 1 patient did not have the first evaluation yet. The 6 patients with stable disease on 
second-line ADT previously had stable disease (4 patients) or PD (2 patients) on first-line ADT. 
One patient received third-line ADT and had stable disease for another 7 months, after also 
having SD, on first- and second-line ADT. 
Ten patients received chemotherapy as second- or third-line treatment after first-line ADT; 2 
of those patients received anti-human epidermal growth factor receptor 2 (HER2) therapy in 
combination with docetaxel; 1 patient was treated only with trastuzumab, and the other patient 
was treated with a combination of trastuzumab and pertuzumab. Five patients had a PR, 3 
patients had stable disease and 2 patients PD.
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DISCUSSION
Salivary duct carcinoma is a rare and aggressive subtype of salivary gland cancer. Results 
on ADT in androgen receptor-positive incurable locally advanced or metastatic salivary duct 
carcinoma are scarce. We aimed to collect data of patients with salivary duct carcinoma over 
a period of 25 years in The Netherlands. In this way, we were able to describe the largest 
retrospective series of patients with salivary duct carcinoma treated with ADT so far and 
describe a separate group of patients who received best supportive care during the same time 
period. In 35 patients treated with first-line ADT for salivary duct carcinoma, 18% had PR and 
32% had stable disease, resulting in a clinical benefit rate of 50% with a median treatment 
duration of 11 months for patients with clinical benefit. The median PFS and OS of the ADT-
treated patients were 4 months and 17 months, respectively. The OS of ADT-treated patients 
was significantly better than of best supportive care patients. However, as not all patients 
responded to ADT, future research should focus on biomarkers that predict the response of 
patients to ADT and mechanisms of intrinsic and acquired resistance to ADT(12). One may 
assume that female patients could have less benefit from ADT due to the lower physiological 
presence of androgen, and, thus, less stimulation of androgen receptor-positive tumor cells. 
However, 2 out of five female patients had sustained PR and no differences in OS and PFS for 
male and female patients were found. 
The incidence of adverse events of ADT-treated patients seemed to be low, although this may be 
due to underreporting in this retrospective case series. On the other hand, ADT is a commonly 
used therapy for patients with prostate cancer, with a well-known low toxicity profile(13). 
Obviously, this study has some limitations. The first one is its retrospective design, which is largely 
due to the rarity of the disease. Performing studies in such rare cancer types is notoriously difficult 
and with a central pathological review, we have done the best attempt as possible to collect data 
of a homogeneous group of patients with salivary duct carcinoma. Second, we compared OS in 
ADT-treated patients with best supportive care patients, which could suggest that bias played 
a role. Unfortunately, we could not retrieve the World Health Organization performance score 
of patients included in this analysis to investigate this issue. However, we did perform a Cox 
regression analysis on OS to adjust for possible confounders, measured at diagnosis of incurable 
locally advanced or metastatic disease. Age, sex, androgen receptor status, metastasized disease 
at diagnosis, and organ involvement were evaluated as possible confounders, but no confounders 
were found. Additionally, the majority of patients that received ADT were treated in 1 hospital 
(74%), because part of the hospitals may not have been familiar with ADT in androgen receptor-
positive salivary duct carcinoma patients, which pleads against selection bias.
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Our objective response rate and clinical benefit rate  on ADT in androgen receptor-positive 
locally advanced or metastatic salivary duct carcinoma patients might be slightly lower 
than  case series described in literature (Table 3). Locati et al. (14) reported 17 patients with 
androgen receptor-positive salivary gland cancer (ie, salivary duct carcinoma and also other 
adenocarcinoma) treated with ADT and found an overall response rate of 65%.  Of the 8 patients 
with salivary duct carcinoma, 2 patients had CR, 2 patients had PR, and 3 patients had stable 
disease. Furthermore, Yajima et al. (15) reported on 8 patients with salivary duct carcinoma, 
with 2patients with PR and 3 patients with stable disease.
In addition to ADT, other therapies may be considered. In a retrospective series of 18 patients 
with salivary duct carcinoma treated with carboplatin and paclitaxel, they had a median 
PFS of 6.5 months and median OS of 34.7 months(16). In case of HER2-positive salivary 
duct carcinoma, which is observed in 21% – 44% of patients with salivary duct carcinoma, 
trastuzumab may be added to chemotherapy(17, 18). In fact, trastuzumab-based treatment 
regimens have shown some promising responses. In 2 separate reports, a total of 8 patients 
were treated with paclitaxel, carboplatin and trastuzumab. Two patients had CR (duration 36 
and 52 months) and 2 patients had PR (duration 20 and 36 months)(19, 20). 
Table 3. Overview of studies on treatment with androgen deprivation therapy for patients with androgen 
receptor-positive salivary duct carcinoma
Author No. of 
patients
ADT  Results
CR (%) PR (%) Stable 
disease (%)
PD (%) Clinical 
benefit, %
Current 
papera
Jaspers  
et al(8)
35b
10
Bicalutamide +/- LHRH 
analogue
Bicalutamide +/- LHRH 
analogue
0
0
6 (18)
2 (20)
11 (32)
3 (30)
17 (50)
5 (50)
50
50
Locati 
et al (14)
8 Bicalutamide or 
cyproterone actate (1pt) + 
LHRH analogue 
2 (25) 2 (25) 3 (38) 1 (13) 87
Yajima 
et al(15)
8 LHRH analogue 0 2 (25) 3 (38) 3 (38) 63
Abbreviations: ADT, androgen deprivation therapy; CR, complete response; LHRH, luteinizing hormone-
releasing hormone; PD, progressive disease; PR, partial response.
aTen patients described in the current article are published before(8).
 bThere were 34 evaluable patients. 
Clinical benefit is CR + PR + stable disease.
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Basket studies may offer a promising way to investigate new treatment options for patients 
with salivary duct carcinoma with targetable mutations. Two case reports mentioned response 
on temsirolimus and bevacizumab in patients with a somatic phosphotidylinositol-3kinase 
mutation, and on vemurafenib in a patient with a somatic B-type Raf mutation (21),(22). Whole 
genome sequencing may reveal other targetable mutations. 
Currently, no treatment algorithms exist for patients with metastatic salivary duct carcinoma. 
Based on our results and literature, we suggest as first-line treatment ADT in androgen 
receptor-positive salivary duct carcinoma due to efficacy and tolerability. The choice of 
bicalutamide monotherapy or LHRH analog with low-dose bicalutamide depends on patient 
characteristics, such as age and sex. Multiple lines of ADT may be given before considering 
chemotherapy. In patients with a more aggressive course of the disease, chemotherapy may 
be considered. In HER2-positive salivary duct carcinoma, trastuzumab and pertuzumab 
may be added to chemotherapy. One of the patients treated with docetaxel, pertuzumab and 
trastuzumab after ADT was discussed in a separate paper(23). Finally, patients can be analyzed 
for targetable mutations and treated accordingly. 
For future research, combining chemotherapy with ADT in androgen receptor-positive salivary 
duct carcinoma may be interesting as an analogue to recent insights in prostate cancer 
(CHAARTED trial)(24). In this randomized trial, first-line ADT was compared to docetaxel plus 
ADT and showed an significant OS benefit for the latter. 
A randomized phase II European Organisation for Research and Treatment of Cancer trial 
(clinical trial number NCT01969578) is currently including patients with androgen receptor-
positive recurrent or metastatic salivary gland carcinomas. Patients are randomized 
between chemotherapy (either cisplatin with doxorubicin or carboplatin with paclitaxel) and 
ADT (triptorelin and bicalutamide). The results of this trial will probably give more insight in 
treatment for androgen receptor-positive salivary gland cancer. 
One may wonder, with the aggressive behavior of salivary duct carcinoma, and the shown 
efficacy of ADT in the metastatic setting, if adjuvant treatment with ADT is warranted. The 
benefit of adjuvant ADT will, however, be difficult to demonstrate.
In conclusion, treatment with ADT in androgen receptor-positive salivary duct carcinoma can 
be recommended given its response, clinical benefit and median OS benefit as compared with 
patients treated with best supportive care. Further research to select patients with androgen 
receptor-positive salivary duct carcinoma who are most likely to benefit from ADT is warranted. 
CHAPTER 3
56
ACKNOWLEDGEMENTS 
We thank M.H. Liedenbaum for providing the radiology images in this article. We thank all 
pathologists and clinicians for their contribution to patient selection and inclusion. Pathologist, 
Affiliation: J. Meijer, Rijnstate, Arnhem, The Netherlands; J.E. van der Wal: Martini, Groningen, 
The Netherlands; L. Arensman, Meander MC,  Amersfoort, The Netherlands; S.M. Willems, 
University Medical Center Utrecht, Utrecht, The Netherlands; E. Bloemena, VU University 
Medical Center, Amsterdam, The Netherlands; L.A. Smit, Netherlands Cancer Institute, 
Amsterdam, The Netherlands; the Tissue Bank, University
Medical Center Groningen, and the Stichting Laboratorium Pathologie Oost-Nederland, The 
Netherlands.
ANDROGEN DEPRIVATION THERAPY IN SALIVARY DUCT CARCINOMA PATIENTS
57
3
REFERENCES 
1. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing 
of salivary duct carcinoma: a report of 50 cases. Cancer. 2005;103:2526-33.
2. Guzzo M, Di Palma S, Grandi C, Molinari R. Salivary duct carcinoma: clinical characteristics and 
treatment strategies. Head Neck. 1997;19(2):126-33.
3. Gilbert MR, Sharma A, Schmitt NC, Johnson JT, Ferris RL, Duvvuri U, et al. A 20-Year Review of 75 
Cases of Salivary Duct Carcinoma. JAMA Otolaryngol Head Neck Surg. 2016;142:489-95.
4. Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, et al. Treatment relevant target 
immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol. 2009;45:986-90.
5. Di Palma S, Simpson RH, Marchio C, Skalova A, Ungari M, Sandison A, et al. Salivary duct carcinomas 
can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes*. 
Histopathology. 2012;61:629-43.
6. Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, et al. Detection of novel actionable 
genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 
2013;19:480-90.
7. Williams MD, Roberts D, Blumenschein GR, Jr., Temam S, Kies MS, Rosenthal DI, et al. Differential 
expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance 
and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007;31:1645-52.
8. Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, van der Graaf WT, et al. Androgen 
receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J 
Clin Oncol. 2011;29:e473-6.
9. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, et al. Pathology 
databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide 
histopathology and cytopathology data network and archive. Cell Oncol. 2007;29:19-24.
10. Nagoa T LL, Loening T, Vielh P, Williams M.D. WHO Classification of Head and Neck Tumours (4th 
edition). IARC: Lyon 2017. In: El-Naggar A. K. CJKC, Grandis J.R., Takata T., Slootweg P.J. (Eds): editor. 
p. Page 173-4.
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-
47.
12. Schalken J, Fitzpatrick JM. Enzalutamide: targeting the androgen signalling pathway in metastatic 
castration-resistant prostate cancer. BJU Int. 2016;117:215-25.
13. Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of 
androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825-36.
14. Locati LD, Perrone F, Cortelazzi B, Lo Vullo S, Bossi P, Dagrada G, et al. Clinical activity of androgen 
deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland 
cancers. Head Neck. 2016;38:724-31.
CHAPTER 3
58
15. Yajima Y FS, Kobayashi T, Ishiki H, Hayashi R, Tahara M. Antiandrogen therapy for the patients with 
recurrent and/or metastatic salivary duct carcinoma expressing androgen receptors: a retrospective 
study. Ann Oncol 2012;23:abstract 1706P. 2012.
16. Nakano K, Sato Y, Sasaki T, Shimbashi W, Fukushima H, Yonekawa H, et al. Combination chemotherapy 
of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences 
in responses by different pathological diagnoses. Acta Otolaryngol. 2016;136:948-51.
17. Clauditz TS, Reiff M, Gravert L, Gnoss A, Tsourlakis MC, Munscher A, et al. Human epidermal growth 
factor receptor 2 (HER2) in salivary gland carcinomas. Pathology (Phila). 2011;43:459-64.
18. Masubuchi T, Tada Y, Maruya S, Osamura Y, Kamata SE, Miura K, et al. Clinicopathological significance 
of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol. 
2015;20:35-44.
19. Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, et al. Trastuzumab for the treatment 
of salivary duct carcinoma. Oncologist. 2013;18(3):294-300.
20. Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic 
review with implications for trastuzumab therapy. Head Neck. 2007;29:907-12.
21. Piha-Paul SA, Cohen PR, Kurzrock R. Salivary duct carcinoma: targeting the phosphatidylinositol 
3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol. 
2011;29:e727-30.
22. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in Multiple Nonmelanoma 
Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373:726-36.
23. van Boxtel W, Boon E, Weijs WLJ, van den Hoogen FJA, Flucke UE, van Herpen CML. Combination of 
docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic 
salivary duct carcinoma. Oral Oncol. 2017;72:198-200.
24. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy 
in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373:737-46.
ANDROGEN DEPRIVATION THERAPY IN SALIVARY DUCT CARCINOMA PATIENTS
59
3

CHAPTER 4
Combination of docetaxel, trastuzumab and pertuzumab 
or treatment with trastuzumab-emtansine  
for metastatic salivary duct carcinoma
Wim van Boxtel, Eline Boon, Willem L.J. Weijs, Frank J.A. van den Hoogen,  
Uta E. Flucke, Carla M.L. van Herpen
Oral Oncology 2017; 72: 198-200.
CHAPTER 4
62
DOCETAXEL, TRASTUZUMAB AND PERTUZUMAB FOR METASTATIC SALIVARY DUCT CARCINOMA
63
4
Dear editor,
With great interest we read the review of Alfieri et al.(1) concerning systemic therapies in 
metastatic salivary gland carcinomas. In addition to this, we hereby present our experience 
with novel HER2-targeted therapies in metastatic salivary duct carcinoma (SDC) patients. SDC 
is a rare and aggressive subtype of salivary gland cancer, with a median overall survival (OS) 
of 3–4 years after primary diagnosis(2-4). As stated in the above mentioned review, responses 
to chemotherapy are poor and knowledge about new drugs is based on small studies. Next 
to this, many studies ‘‘lumped” patients with a spectrum of salivary gland cancers, failing to 
fully appreciate the impact of the heterogeneity in salivary gland cancer(5). In SDC, HER2 is 
overexpressed in 21–44% (4, 6, 7) of the cases, and could serve as a therapeutical target (8). 
In table 1 we show the available evidence on HER2-targeted therapies for metastatic SDC. 
The most important study is a phase II clinical trial in 45 patients treated with docetaxel and 
trastuzumab for advanced HER2-positive SDC, in which preliminary results show an overall 
response rate of 69% and a median progression free survival (PFS) of 11.3 months(9). In breast 
cancer, patients receiving docetaxel and trastuzumab for HER2-positive metastatic breast 
cancer have a median PFS of 12.4 months and median OS of 40.8 months. Adding pertuzumab 
to this regimen extents the median PFS and OS to 18.7 and 56.5 months, respectively (10). 
Because of similarities in histology and HER2 status, we hypothesized that adding pertuzumab 
may also increase PFS in SDC. In this letter to the editor we describe two patients treated 
with the combination of docetaxel, trastuzumab and pertuzumab in our clinic. Additionally, 
we demonstrate in one patient that after disease progression another line of HER2-targeted 
therapy with  trastuzumab-emtansine can be beneficial. 
Both patients were treated with the combination of docetaxel, trastuzumab and pertuzumab. 
Docetaxel was dosed 75 mg/m2 intravenously (IV) every 3 weeks. The HER2-targeting 
monoclonal antibodies trastuzumab and pertuzumab were dosed 600 mg sub-cutaneously and 
420 mg IV every 3 weeks, respectively. For pertuzumab, patients received a loading dose of 840 
mg in the first cycle. After 6 cycles docetaxel was stopped and trastuzumab and pertuzumab 
were continued until PD. After PD, one patient was treated with trastuzumab-emtansine. This 
is an antibody-drug conjugate consisting of trastuzumab linked to the microtubule inhibitor 
emtansine. It was dosed 3.6 mg/kg IV every 3 weeks. 
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Table 1. Literature review on HER2-targeted therapies in metastatic salivary duct carinoma.a
Author Study Number  
of 
patients
Therapy Clinical benefit Median 
PFS
Agulnik  
et al. (12)
Phase II trial 4 Lapatinib No CR or PR Unknown
Limaye  
et al. (13)
Case series 5 Trastuzumab, paclitaxel 
and carboplatin
1 x CR
2 x PR
2 x PD
18 months
Perissinotti  
et al.(14)
Case series 11 3 patients: Trastuzumab 
only
3 x SD Unknown
8 patients: Trastuzumab 
and chemotherapyb
2 x PR
3 x SD
5 x PD
1 x non-evaluable
Falchook  
et al., (15)
Phase I trial 3 Trastuzumab,  lapatinib 
and bevacizumab
1 x PR
1 x SD
1 x PD
3 months
De Block  
et al. (16)
Case series 3 Trastuzumab and 
chemotherapyb
3 x PR 11 months
Takahashi  
et al. (9)
Phase II trial 45 Trastuzumab and 
docetaxel
31 x CR/PR à 
Response rate 69%
11.3 
months
CR: complete remission, PR: partial response, SD: stable disease, PD: progressive disease, PFS: 
progression free survival. 
aCase-reports were excluded. 
b different combinations of chemotherapy were used. 
Case 1. A 63-year-old man was diagnosed with a pT3N2bM0 androgen receptor (AR) positive 
SDC of the right parotid gland and primary treatment consisted of a parotidectomy with a 
modified neck dissection of level I–V, followed by adjuvant radiation therapy (66 Gy in fractions 
of 2 Gy). Only 8 months later, patient was diagnosed with metastases in liver, lungs and 
mediastinal lymph nodes for which palliative androgen deprivation therapy (ADT) was started. 
After 6 months, the patient had PD and ADT was stopped. Because HER2 was strongly positive 
(immunohistochemistry (IHC) 3+ and fluorescence in situ hybridization (FISH) positive), we started 
with the combination of docetaxel, trastuzumab and pertuzumab. After 2 cycles the patient had 
a partial response (PR). Currently, he  has an ongoing PR 17 months after start of treatment, 
and received 25 cycles. Side effects consisted of a flare-up of radiotherapy toxicity induced by the 
systemic treatment and a pre-aurical and retropharyngeal abscess after 2 cycles. After 10 cycles 
the patient developed erysipelas of the right side of his face. At this moment he as a very good 
quality of life with no adverse events and a WHO performance score of 0. 
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Case 2. A 48-year-old woman was diagnosed with a pT3N1M0 SDC ex pleomorphic adenoma. 
Primary treatment consisted of a right parotidectomy with homolateral neck dissection, followed 
by adjuvant radiation therapy. Fifteen months after the initial diagnosis multiple pulmonary 
metastases were detected. Because of strong HER2 overexpression and amplification (IHC 3+ 
and FISH positive) and only weak AR expression, palliative treatment with the combination of 
docetaxel, trastuzumab and  pertuzumab was initiated. The evaluation CT-scan showed SD with 
a decrease in the sum of target lesions by 22%. After the sixth cycle she developed erysipelas 
of the right side of her face. Eight months after start of treatment, progression of pulmonary 
metastases was detected. Trastuzumab en pertuzumab were stopped and ADT was started, 
but the first evaluation after 3 months showed an increase of the pulmonary lesions and a new 
brain metastasis. Therefore, ADT was stopped and she received stereotactic radiation therapy 
on the brain metastasis. The primary tumor was analyzed with the ‘Radboud Cancer Hotspot 
gene panel’, but no druggable mutations were found. Leaving HER2 as the only druggable 
target, we decided to start with trastuzumab-emtansine once every 3 weeks. After 6 cycles of 
trastuzumab-emtansine she had a PR with a decrease in the sum of target lesions of 70% (Fig 
1). Currently, after 12 cycles she has an ongoing PR. 
a) b)
Figure 1. (a) Chest CT with a section width of 5 mm, pulmonary window, after intravenous contrast 
administration of the second patient before starting trastuzumab-emtansine. Pulmonary metastasis with 
cavitation in the left lower lobe of 29 mm in the largest axial direction and a more opacified metastasis in 
the right lower lobe measuring 34 mm in the largest axial direction. (b) Chest CT with a section width of 5 
mm, pulmonary window, after intravenous contrast administration of the second patient after 4 months of 
treatment with trastuzumab-emtansine. Pulmonary metastasis in the left lower lobe measuring 16 mm. 
The pulmonary metastasis in the right lower lobe is immeasurable.
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DISCUSSION
We presented two patients with metastatic SDC, which were treated with the combination of 
docetaxel, trastuzumab and pertuzumab. On this regimen, one patient has an ongoing PR 
after 17 months of treatment and one patient had PD after 8 months. In the last patient, we 
show that a subsequent line of HER2-targeted therapy can be beneficial, as this patient has 
a sustained PR after 8 months of treatment with trastuzumab-emtansine. Remarkably, both 
patients developed erysipelas at the site of the resected primary tumor. Erysipelas is a known 
side effect of trastuzumab (11) but not for pertuzumab. Whether dual HER2 blockade increases 
the risk of this side effect, especially in a previously operated and irradiated area, is not known. 
In conclusion, we showed that dual HER2 blockade and multiple lines of HER2-targeted 
therapies can be beneficial to patients with metastatic HER2-positive SDC. More research 
is needed to establish the advantage of the combination of docetaxel, trastuzumab and 
pertuzumab over docetaxel and  trastuzumab alone. The efficacy of trastuzumab-emtansine in 
SDC has to be assessed, however we showed efficacy in one patient after PD with dual HER2 
blockade. 
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ABSTRACT
Objectives
In 2010, a new subtype of salivary gland cancer (SGC), (mammary analogue) secretory carcinoma 
(SC), was defined, characterized by the ETV6-NTRK3 fusion gene. As clinical behavior and 
outcome data of this histological subtype tumor are still sparse, we aimed to describe the 
clinicopathological course and outcome of a series of translocation positive SC patients.
Patient and methods
We re-evaluated the pathological diagnosis of a subset of SGCs, diagnosed in 4 of 8 Dutch 
head and neck centers. Subsequently, tumors with a morphological resemblance to SC were 
tested for the ETV6-NTRK3 fusion gene using RT-PCR. Furthermore, patients prospectively 
diagnosed with SC were included. The clinical characteristics and outcomes were retrieved 
from the patient files. 
Results
Thirty-one patients with ETV6-NTRK3 fusion gene positive SC were included. The median age 
was 49 years, 17 patients (55%) were male. Eighteen tumors (58%) arose in the parotid gland. 
One patient presented with lymph node metastasis. All patients underwent tumor resection 
and 4 patients had a neck dissection. Four patients had re-resection and 15 patients (48%) 
received postoperative radiotherapy. One patient developed a local recurrence, no regional 
recurrences or distant metastases were observed. After a median follow-up of 49 months the 
5- and 10-year overall survival were 95%, the 5- and 10-year disease free survival were 89%.
Conclusion
The clinical course of SC is favorable with a low rate of locoregional recurrence and excellent 
survival. Given the low incidence of nodal metastases, elective neck treatment, i.e. surgery 
and/or radiotherapy, does not seem to be indicated.
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INTRODUCTION
Salivary gland cancers comprise a wide histological spectrum with more than twenty different 
subtypes(1). In 2010, a new entity of salivary gland cancer was described by  Skálová et al, 
characterized by the presence of the ETV6-NTRK3 fusion gene (2). The histopathological 
appearance resembles secretory carcinoma of the breast, and both tumors share the ETV6-
NTRK3 fusion gene, hence the proposed name was mammary analogue secretory carcinoma 
(MASC). In the updated 2017 WHO classification, MASC is acknowledged and referred to as 
‘secretory carcinoma’, to standardize nomenclature amongst different organ sites (1). 
The morphological features of secretory carcinoma include a variety of architectural growth 
patterns, intracytoplasmic vacuoles, lack of intracytoplasmic zymogen granules in a mucinous 
or hemosiderin-laden histiocyte-rich background (3). Immunohistochemical markers such as 
S100, vimentin, STAT5a, MUC4 and mammaglobin may be helpful in preselecting patients with 
suspected secretory carcinoma, but none of these markers can fully confirm the diagnosis. 
However, the presence of the ETV6-NTRK3 fusion gene is pathognomonic (4). The most 
important entities in the differential diagnosis of secretory carcinoma are acinic cell carcinoma 
(AciCC), polymorphous adenocarcinoma (PAC), and adenocarcinoma not otherwise specified 
(NOS). Although in salivary gland cancer the presence of the fusion gene is specific for secretory 
carcinoma, the ETV6-NTRK3 fusion gene has also been demonstrated in several other solid 
and hematological malignancies, such as secretory carcinoma of the breast, papillary thyroid 
carcinoma, congenital fibrosarcoma, congenital mesoblastic nephroma, acute myeloid 
leukemia and sino-nasal low-grade adenocarcinoma(5-8).  
In recent years, several reports have been published on characteristic histopathological 
features of secretory carcinoma within the many subtypes of SGC, but little is known about the 
clinical behavior of this new entity, including the outcome of these patients. A review of 279 
cases showed a male to female ratio of 1.5:1 and occurrence mostly (68%) in the parotid gland 
(9). Disease free survival (DFS) in secretory carcinoma patients was reported to be similar to 
DFS in AciCC in a comparison in respectively 29 and 38 patients (10). The aim of the current 
study is to focus on clinical behavior and outcome of patients with secretory carcinoma.  
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PATIENTS AND METHODS 
In four hospitals in the Netherlands, patients with subsets of salivary gland cancer (AciCC, 
PAC and adenocarcinoma) were retrospectively evaluated for morphological resemblance to 
secretory carcinoma by pathologists (U.F, L.S, E.B. and S.M.W.) from 2000 until 2016. Patients 
suspected of secretory carcinoma were tested for the presence of the ETV6-NTRK3 fusion gene. 
The ETV6-NTRK3 fusion gene was analyzed using reverse transcriptase-polymerase chain 
reaction (RT-PCR). RNA was extracted from formalin-fixed and paraffin-embedded tissues 
(FFPE) using RNA-Bee-RNA isolation reagent (Bio-Connect BV, Huissen, the Netherlands) 
according to standard procedures. RNA quantity and quality were determined by NanoDrop 
measurement (Fisher Scientific, Landsmeer, the Netherlands) and, subsequently, cDNA 
synthesis was performed using Superscript II (Invitrogen Life Technologies Europe, Bleiswijk, 
the Netherlands) and random hexamers (Promega Nederland, Leiden, the Netherlands). 
The cDNA was tested by the reverse transcription-polymerase chain reaction (RT-PCR) for 
the HMBS (hydroxymethylbilase synthase) housekeeping gene using the primers forw150 
5’-TGCCAGAGAAGAGTGTGGTG-3’, rev150 5’-ATGATGGCACTGAACTCCTG-3’, forw250 5’- 
CTGGTAACGGCAATGCGGCT-3’, rev250 5’- TTCTTCTCCAGGGCATGTTC-3’.
For detection of the ETV6-NTRK3 fusion, the following primers were used: ETV6 forward 
primer P385: 5’-ACCACATCATGGTCTCTGTCTCCC-3’and NTRK3 reverse primer P386: 
5’-CAGTTCTCGCTTCAGCACGATG-3’. The PCR products were analyzed by agarose gel 
electrophoresis.
Patients who were prospectively diagnosed with secretory carcinoma were also included. For 
both retrospective and prospective cases, the presence of the ETV6-NTRK3 fusion gene was 
mandatory for inclusion in this study. Patients’ characteristics regarding clinical presentation, 
diagnosis, treatment and follow-up were collected by evaluating medical records. According 
to the Dutch guidelines, review by a medical ethical committee was not necessary due to the 
retrospective nature of this study (www.federa.org). 
Resection margins were categorized as free (>5 mm), close (1-5 mm) or involved (<1 mm) 
based on the pathology reports. For further survival analysis, close and involved margins were 
grouped as ‘not free’. 
For the prospectively collected cases the date of diagnosis was defined as first date of 
histopathological confirmation of the diagnosis secretory carcinoma. In retrospective cases, 
the date of obtaining the original histopathological material was used as date of diagnosis. 
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Statistics
Overall survival (OS) is defined as the time from date of diagnosis until date of death of any 
cause. Patients alive at the last known follow-up date were censored. DFS is defined as the 
time from date of surgery until date of recurrence (local or regional recurrence or distant 
metastasis) or death of any cause, whichever comes first. Patients alive without disease 
recurrence at last known follow-up were included in the analysis as censored. OS and DFS 
were estimated using Kaplan Meier survival curves. Statistical analysis was performed using 
SPSS data analysis software version 22.0. 
RESULTS
Patients and tumor characteristics 
In total, 42 patients were tested; 3 patients tested negative, for 6 patients the fusion gene 
could neither be confirmed nor invalidated, in 33 patients we confirmed the presence of the 
ETV6-NTRK3 fusion gene. Unfortunately, clinical records were not available for 2 of the 33 
confirmed patients; thus, a total of 31 patients with ETV6-NTRK3 fusion gene positive secretory 
carcinoma were included. The median age at diagnosis was 49 years (range 19–83 years), 17 
patients (55%) were male. Eighteen tumors (58%) were located in the parotid gland, one in 
the submandibular gland, and the remaining 12 tumors in the minor salivary glands.  The 
primary site of the minor salivary gland tumors were the lip (n = 5), the oral mucosa (n = 2), 
the soft palate (n = 1), the hard palate (n = 1 ) and the remaining three could not be further 
specified. Nineteen patients (61%) had T1 tumors, 10 patients (32%) T2 tumors; for 2 patients 
the T-classification was not available. Only one patient presented with regional lymph node 
metastasis, none of the patients had distant metastasis at diagnosis. In most patients, the 
presenting symptom was a painless mass (22 patients). One patient presented with a painful 
swelling and one with a non-healing wound. For the remaining 9 patients no symptoms could 
be retrieved from the medical records. The median time from start of symptoms to diagnosis 
was 14 months (range 6 weeks – 20 years). 
Eleven patients were prospectively diagnosed with secretory carcinoma between 2011 and 2016. 
The remaining 20 patients were retrospectively diagnosed with secretory carcinoma, confirmed 
by the presence of the ETV6-NTRK3 fusion gene. The initial diagnosis of these patients was 
between 2000 and 2012. Of these 20 patients, 16 patients were previously diagnosed with 
AciCC, three as PAC and one as adenocarcinoma NOS.
Baseline characteristics of all patients are shown in Table 1.
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Table 1. Patients’ and tumor characteristics.
Median age, in years [ range] 49 [ 19 – 83 ] 
Gender, n (%) 
Male 
Female
17 (55)
14 (45)
Tumor localization, n (%) 
Major salivary glands 
- Parotid
- Submandibular gland
- Sublingual gland 
Minor salivary glands
18 (58)
1 (3)
0 (0)
12 (39)
Method of diagnosis of secretory carcinoma, n (%)
Prospective
Retrospective 
- Acinic cell carcinoma 
- Polymorphous adenocarcinoma 
- Adenocarcinoma, not otherwise specified 
11 (35)
16 (52)
3 (10)
1 (3)
Signs and symptoms
Painless mass 
Painful mass 
Non-healing wound
Unknown
22 (71)
1 (3)
1 (3)
7 (23)
Median duration of symptoms, (range) 14 months 
(6 weeks – 20 years )a
TNM stage, n
T1/T2/T3/T4/Tx
N0/N1/N2/N3
M0/M1 
19/10/0/0/2
30/0/1/0
31/0
Surgery, n (%)
Yes
No 
31 (100)
0 (0)
Resection margins, n (%)
Free (> 5 mm)
Not Free 
- Close (1-5 mm)
- Involved (<1 mm)
Not available 
13 (42)
9 (29)
7 (23) 
2 (6) 
Revision surgery, n (%)
Yes 
No
4 (13)
27 (87)
Postoperative radiotherapy, n (%)
Yes
No
15 (48)
16 (57)
a based on 20 patients.
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Primary treatment
Primary treatment for all 31 patients consisted of surgery. Seventeen patients had a surgical 
resection of the affected salivary gland, and in four of them surgery also included a neck 
dissection (only one patient had tumor positive lymph nodes). Eleven patients had either a local 
excision, excision or incision biopsy of the tumor. For three patients, the exact type of surgery 
could not be determined. Seven patients (23%) had involved resection margins, nine patients 
had closely excised tumors (29%) and 13 (42%) had free resection margins. In two patients, 
information about resection margins was not available. Four patients (13%) had additional 
surgery, because of involved resection margins (2), a close excision margin (1) and an uncertain 
margin after excision biopsy. Fifteen patients (48%) received postoperative radiotherapy: all 
seven patients with involved resection margins, six out of nine patients with closely excised 
tumors and two patients with free resection margins. One of the patients with free resection 
margins had a difficult preparation of the facial nerve during surgery, and was therefore 
treated with postoperative radiotherapy. For the other patient with free resection margins the 
exact reason for postoperative radiotherapy could not be retrieved from the patient files. Of the 
four patients who underwent re-excision, two patients additionally underwent postoperative 
radiotherapy. The characteristics of patients with postoperative radiotherapy and patients with 
surgery only are summarized in Table 2. The median dose of radiotherapy was 66 Gy (range 60 
– 66 Gy). More detailed information about the radiotherapy target volume was available in eight 
out of 15 patients with radiotherapy. In four patients, the target volume included the ipsilateral 
neck; in the other four patients, only the surgical bed was irradiated. None of the patients 
received chemotherapy.
 
Disease recurrence
Only one patient (4%) had a local recurrence, occurring 50 months after primary surgery 
(resection margins of the primary surgery were not available), without postoperative radiotherapy. 
The patient remained disease-free during the 40 months following surgical resection of the 
recurrence. None of the patients had a regional recurrence or distant metastasis. 
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Table 2. Characteristics of patients with secretory carcinoma with ETV6-NTRK3 fusion gene mutation 
receiving postoperative radiotherapy versus patients with surgery only.
Postoperative 
radiotherapy
n = 15 
Surgery only
n = 16
Median age, in years [ range] 52 (20 – 83] 46 [ 19 – 68]
Gender, n (%) 
Male 
Female
8 (53)
7 (47)
9 (56)
7 (44)
Tumor localization, n (%) 
Major salivary glands 
Parotid
- Submandibular gland
- Sublingual gland 
Minor salivary glands
11 (73) 
1 (7)
0 (0)
3 (20)
7 (44)
0 (0)
0 (0)
9 (56)
Method of diagnosis of secretory carcinoma, n (%)
Prospective
Retrospective 
- Acinic cell carcinoma 
- Polymorphous adenocarcinoma
- Adenocarcinoma, NOS
5 (33)
10 (67)
10 (67)
0 (0)
0 (0)
6 (38)
10 (63)
6 (38)
3 (19)
1 (6)
Signs and symptoms, n (%)
Painless mass 
Painful mass 
Non-healing wound
Unknown
12 (80)
0 (0)
0 (0)
3 (20)
10 (63)
1 (6)
1 (6)
4 (25)
Median duration of symptoms, (range ) 2 years  
(6 weeks – 20 years)
6 months  
(3 months – 2 years)
TNM stadium, n
T1/T2/T3/T4/Tx
N0/N1/N2/N3
M0/M1 
7/7/0/0/1
14/0/1/0
15/0/0/0
12/3/0/0/1
16/0/0/0
16/0/0/0
Surgery, n (%)
Yes
No 
15 (100)
0 (0)
16 (100)
0 (0)
Resection margins, n (%)
Free ( >5mm)
Not Free 
- Close  (1-5 mm)
- Involved (<1 mm)
Not available 
2 (13)
6 (40)
7 (47)
0 (0)
11 (69)
3 (19)
0 (0)
2 (13)
Additional resection, n (%)
Yes 
No
2 (13)
13 (87)
2 (13)
14 (87)
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Survival
After a median follow up time of 49 months, 1 patient died (without signs of disease recurrence). 
The estimated 5- and 10- year OS were 95%. The 5- and 10-year disease-free survival were 
89%. OS and DFS are displayed in Figs. 1a-1f. 
The estimated 5-year OS and DFS were 89% for patients with free resection margins, and 100% 
for patients with resection margins that were not free (either close or involved), respectively. 
The estimated 5-year OS and DFS of patients treated with surgery and radiotherapy were both 
89%, for patients treated with surgery only these were 100% and 89%, respectively. 
The OS and DFS for patients according to resection margins and radiotherapy are also 
illustrated in Figs. 1a-1f.  
CHAPTER 5
80
	
	
Figure 1 
1a Overall survival of all secretory carcinoma patients. 
 
 
 
1b. Disease Free Survival all secretory carcinoma patients. 
 
       
  
Figure 1a. Overall survival of all secretory carcinoma patients.
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1b. Disease Free Survival all secretory carcinoma patients. 
 
      
  
Figure 1b. Disease Free Survival all secretory carcinoma patients.
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Figure 1c – Overall survival categorized by resection margins being free or not free.  
 
Figure 1d – Disease free survival categorized by resection margins being free or not 
free.  
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Figure 1c – Overall survival categorized by resection margins being free or not free.  
 
Figure 1d – Disease free survival categorized by resection margins being free or not 
free.  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1d. Disease free survival categorized by resection margins being free or not free. 
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Figure 1e – Overall survival categorized by primary treatment with surgery versus 
surgery and radiotherapy.  
 
Figure 1f – Disease free survival categorized by primary treatment with surgery 
versus surgery and radiotherapy. 
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Figure 1e – Overall survival categorized by primary treatment with surgery versus 
surgery and radiotherapy.  
 
Figure 1f – Disease free survival categorized by primary treatment with surgery 
versus surgery and radiotherapy. 
 
 
	
Figure 1f. Disease free survival categorized by primary treatment with surgery versus surgery and 
radiotherapy.
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DISCUSSION 
In this report of 31 patients with ETV6-NTRK3 fusion gene positive secretory carcinoma, we 
presented the clinical spectrum of secretory carcinoma. The outcome of disease was favorable 
and only one of the patients had local recurrence of the disease. 
There was a male to female ratio of 1.2:1, which is in accordance with most reports showing a 
larger proportion of male patients. In a literature review of 279 cases, the male to female ratio 
was 1.5:1 (9). 
As for secretory carcinoma of the breast, in secretory carcinoma pediatric cases may be 
encountered (11, 12). However, we had no pediatric cases, but we did encounter 6 adolescent 
and young adults (18-35 years). 
We only observed T1 and T2 tumors in our cohort, although T3 and T4 tumors were described 
by others (2, 10). Only one patient of our series had cervical lymph node metastasis at time of 
diagnosis, and was surgically treated. In another described series of 36 secretory carcinoma 
patients, 18 patients had a neck dissection, of which 4 patients had tumor positive lymph 
nodes(10). 
In the current study, the largest proportion of retrospective cases of secretory carcinoma 
were previously classified as AciCC and the remaining cases were mostly identified as PAC. 
AciCC was therefore the most important differential diagnosis in this report. AciCC may be 
morphologically differentiated by structural and cytologic diversity and by the presence of large 
serous acinar cells containing zymogen granules which are absent in secretory carcinoma. 
Remarkably, we found that 39% of tumors occurred in the minor salivary glands. This is in 
agreement with data in the review of 279 secretory carcinoma patients (9). In a Danish national 
cohort study 86/97 (89%) of AciCCs presented in the parotid gland (13). Secretory carcinoma 
seems to be occurring more frequently outside the parotid gland than AciCC. Therefore, if 
patients are diagnosed with a AciCC located in the minor salivary glands there should be a 
suspicion of secretory carcinoma.
Notably, eleven patients started with local excision, or incision biopsies. Although the reasons 
were not entirely clear, this may possibly be attributed to ambiguity on previous cytology or 
clinical appearance.
In this report, only one patient had a local recurrence 50 months after the primary treatment, 
which was successfully treated and remained disease free during follow up. Distant metastasis 
did not occur in our patients. However, it should be noted that one should be cautious 
interpreting these data, as the median follow up time in this study is only 49 months, and given 
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the low grade behavior of secretory carcinoma, local recurrences might develop even after a 
more prolonged period of follow up. Actually, patients have been described in the literature 
diagnosed with tumors with high grade transformation, in some cases dying of disseminated 
disease within 2 and 6 years. (14, 15). 
In the current study, the course of the disease is favorable in terms of OS and DFS, and appears 
to be comparable to outcomes of AciCC. However, it should be noted that morphologically high 
grade cases of secretory carcinoma were not encountered. A survival analysis of 1353 cases 
AciCC based on the National Cancer Data Base (NCDB) in the United States showed a 5 – year 
overall survival of 83.3% and 5 – year disease specific survival of 91.4% (16). 
Although clinical outcomes between patients with AciCC and PAC versus secretory carcinoma 
may not differ greatly, it is important to distinguish secretory carcinoma patients from other 
salivary gland cancers, mainly in the case of metastatic disease. The presence of the NTRK-ETV6 
fusion gene has revealed an actionable target and currently, a phase II trial with entrectenib is 
actively recruiting patients for those patients harboring NTRK fusion genes. Entrectinib is an 
orally available inhibitor of the tyrosine kinase tropomyosin-related kinases (TRK) (17).
The role of adjuvant radiotherapy is controversial for AciCC. An analysis of 1241 cases of 
parotid AciCC from the SEER database showed no statistical difference in overall survival for 
patients with surgery compared to patients undergoing surgery and adjuvant radiotherapy 
(18). It should however be noted that this  is most likely confounding by indication, with worst 
cases having received radiotherapy. In the current series, 48 percent of patients received 
postoperative radiotherapy. One could argue that the excellent outcomes of these secretory 
carcinoma patients is due to the beneficial effects of the postoperative radiotherapy or 
perhaps the intrinsic biological behavior of secretory carcinoma. Due to the low number of 
events (either local recurrences and/or death) and the differences in baseline characteristics, 
specifically resection margins, our data should be interpreted with caution. However, it is likely 
that patients with clinically N0 disease may be spared from elective treatment, i.e. surgery or 
radiotherapy of the neck, given the very low incidence of nodal metastases. Future research 
may clarify the importance of adjuvant neck treatment for secretory carcinoma. 
The limitation of this study may be the selection of patients. Secretory carcinoma has been 
recognized as a distinct entity of salivary gland cancer since the association with the ETV6-
NTRK3 fusion gene in 2010. Only a limited number of patients in the current series were 
diagnosed with secretory carcinoma prospectively. The other patients were identified after 
reviewing the resection specimen of a subset of salivary gland cancer and testing them for the 
presence of the ETV6-NTRK3 fusion gene. Therefore, a selection bias may play a role in the 
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data as presented in this paper. Furthermore, due to the retrospective nature of the study some 
cases had missing data.
However, with the presentation of 31 patients with confirmed ETV6-NTRK3 fusion gene 
secretory carcinoma and detailed data on the diagnosis, treatment and outcomes, we feel 
this makes these results give more clinical background and a meaningful contribution to the 
existing literature of secretory carcinoma.
CONCLUSION
We present the clinical course of 31 patients with ETV6-NTRK3 fusion gene confirmed secretory 
carcinoma. The clinical course is favorable with a low rate of recurrences and an excellent 
overall and disease free survival after a median follow up of 49 months. Elective treatment of 
the neck does not seem to be indicated considering the low incidence of nodal metastases, 
good prognosis, and apparent low grade behavior of secretory carcinoma.
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ABSTRACT
Background 
There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and 
intermediate-grade osteosarcoma of the head and neck.
Methods 
All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck 
in the Netherlands between 1993 and 2013 were reviewed. 
Results
We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall 
survival (OS) was 55%. In 50 patients with surgically resected high- or intermediate- grade 
osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, 
adjusting for age and resection margins, showed that patients who had not received chemotherapy 
had a significant higher risk on local recurrence (hazard ratio [HR] = 3.78 and HR 3.66, respectively). 
Conclusion
In patients younger than 75 years of age with surgically resected high- and intermediate-grade 
osteosarcoma of the head and neck, treatment with (neo-)adjuvant chemotherapy resulted 
in a significantly smaller risk of local recurrence. Therefore, we suggest (neo-) adjuvant 
chemotherapy in patients amenable to chemotherapy. 
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INTRODUCTION
Osteosarcoma is an aggressive bone tumour characterized by the formation of osteoid by 
malignant osteoblasts (1). It most commonly occurs in the extremities and mainly effects 
teenagers and young adults. Osteosarcoma of the head and neck accounts for approximately 
6% of all osteosarcomas (2).
The current treatment for extremity osteosarcomas is neo-adjuvant chemotherapy followed by 
surgery and adjuvant chemotherapy. One of the main aims of chemotherapy is early treatment 
of occult distant metastases. Since the introduction of chemotherapy, the overall survival 
(OS) improved dramatically with a 5-year overall survival of about 60% to 70% currently(3). 
Osteosarcoma of the head and neck behaves differently from extremity osteosarcoma. First, 
the median age is at least 2 decades higher (4). Second, although patients with extremity 
osteosarcoma have a very high risk of metastatic disease of the lungs (44% to 49%)(5), pulmonary 
metastases are less common in patients with OSHN (4% to 43%) (6, 7). Furthermore, local 
recurrences predominate in osteosarcoma of the head and neck with a reported incidence 
of 17% to 70% (2, 8) compared with 5% to 7% in extremity osteosarcoma (5). This could be 
attributed to the difficulty to obtain tumor-free margins by surgery in the head and neck region.
In view of these differences, there is an ongoing debate about the value of (neo-)adjuvant 
chemotherapy in the treatment for osteosarcoma of the head and neck. The opponents 
of chemotherapy argue that, because pulmonary metastases only occasionally develop, 
chemotherapy has no role in the primary treatment of osteosarcoma of the head and neck. 
Because of the rarity of the disease, only small retrospective case series have been described 
(7, 9, 10). The single meta-analysis (173 patients) and systematic review (201 patients) show 
conflicting results about the use of (neo-)adjuvant chemotherapy (4, 11).
The purpose of this retrospective study - with a review of each individual medical report - was 
to describe the treatment and outcomes of patients who were diagnosed with osteosarcoma 
of the head and neck in The Netherlands over the last 2 decades, with special attention to the 
role of (neo-)adjuvant chemotherapy.
PATIENTS AND METHODS 
A retrospective cohort study was conducted in patients diagnosed with osteosarcoma of the 
head and neck from 1993 until July 2013 within the Dutch Head and Neck Society. 
Local pathologists of the 8 participating head and neck centres were asked to provide a 
search with the term ‘osteosarcoma’ in combination with head and neck locations, such as 
“jaw”, ”mandible”, “maxilla”, “larynx” or “skull”. Patients older than 16 years of age with a 
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histopathological proven diagnosis of osteosarcoma and with a primary location in the head 
and neck region were included. In the Netherlands, there is a special multidisciplinary 
expert team available for reviewing cases with bone tumours (‘Netherlands Committee on 
Bone Tumours (NCBT)’). For all patients in this study, histological evaluation was (also) 
performed and confirmed by either the NBCT or an experienced pathologist’s part of 
the NBCT in their affiliated hospitals. For all cases in which histological grade was either 
intermediate, or not reported, haematoxylin and eosin stained slides were retrieved from 
the archives and revised by 2 experienced musculoskeletal pathologists (J.B. and U.F.). 
All medical records were reviewed for patients’ characteristics, such as age, sex, and 
medical history, as well as information concerning diagnosis (location, grading and subtype), 
treatment (surgery, radiotherapy and chemotherapy), occurrence of local recurrence or distant 
metastases, and survival.
Data analysis
Resection margins were classified by pathological assessment and categorized in three 
categories; intralesional, marginal or wide according to Enneking et al (12). Intralesional 
and unknown resection margins were considered incomplete, whereas marginal and wide 
resection margins were considered complete. OS was defined as time (in months) from date 
of diagnosis until date of death of any cause; patients alive at last known follow-up date were 
censored. Disease-free-survival (DFS) was defined as time (in months) from surgery until date 
of the first event (local recurrence, distant metastases or death), patients alive without disease 
at last known follow-up date were censored. Local recurrence and distant metastases were 
measured by radiological evaluation and preferably confirmed by pathological assessment. 
Patients without surgical resection were not included in DFS calculations or survival figures. 
Local recurrence-free interval (LRFI) was defined as time (in months) from surgery until the 
occurrence of a local recurrence. Patients without a local recurrence were censored at date of 
death or last known follow-up date.
Statistical analysis
The Kaplan-Meier method was performed to create survival figures. Log rank tests were used 
to compare the survival curves between groups. The adjustment of the HR for chemotherapy 
for confounders was restricted to age and resection margins in a Cox regression model, due to 
the limited number of events. The analysis of the effect of chemotherapy on OS, DFS en LFRI 
was limited to surgical-resected patients with high or intermediate grade osteosarcoma of the 
head and neck and < 75 years of age, because  (neo-)adjuvant chemotherapy for elderly patients 
is not considered in this setting. The size of the effect of chemotherapy was defined as the ratio 
between the hazard of the event in the patients who were not treated with chemotherapy and 
the hazard of the event in the chemotherapy treated patients. It was calculated using a Cox 
proportional hazards regression model. HRs are reported with 95% confidence interval (95% 
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CI). A p value of <.05 was considered to be significant. The data were analysed using SPSS 
version 20. 
RESULTS 
Patients’ characteristics and treatment of the 77 patients with osteosarcoma of the head 
and neck
A total of 77 patients with osteosarcoma of the head and neck were identified. Thirty-six 
patients (47%) were men and the median age at diagnosis was 46 years (range 16-95 years). 
Patients’ characteristics are summarized in Table 1. A total of 25 patients (33%) had a previous 
malignancy. The median age at the time of diagnosis of this first non-osteosarcoma of the head 
and neck primary tumor was 30 years (range, 1-77 years). Seven patients had multiple primary 
malignancies. One case of Li-Fraumeni syndrome was identified. Four patients were treated 
for retinoblastoma in childhood. Twenty-two patients (29%)  previously received radiotherapy, 
of which 19 (86%) were in the head and neck region. The median age at time of previous 
radiotherapy of the head and neck was 30 years (range, 1-77 years). The median time between 
the prior radiotherapy and the presentation of the osteosarcoma of the head and neck was 16 
years (range, 7-60 years). The most common tumor location was the jaw (73%; Table 1). Fifty-
eight tumors (75%) were classified as high- grade, 6 (8 %) as intermediate-grade and 11 (14%) 
as low-grade osteosarcoma. At time of diagnosis, none of the patients had involvement of the 
lymph nodes in the neck and only one patient presented with pulmonary metastases.
Patients were treated according to the local policy of the multidisciplinary head and neck 
cancer working group. Seventy patients (91%) underwent surgical resection. In total, 17 
patients (22%) received radiotherapy. The median dose was 58 Gy (range, 8-70 Gy). Fourteen 
patients received postoperative radiotherapy because of irradical resection; 2 other patients 
received radiotherapy as single treatment; and 1 patient received radiotherapy because of 
tumor bleeding.
The 5-year OS was 55% for all 77 patients. 
Low grade osteosarcoma of the head and neck 
All patients with low-grade osteosarcoma of the head and neck (n = 11) underwent surgical 
resection. Only 1 patient (9%) received postoperative radiotherapy because of an intralesional 
resection. None of them were treated with chemotherapy. After a median follow-up time of 106 
months (range, 15–198 months) none of the patients developed a local recurrence or distant 
metastases. One patient had a second primary malignancy. One patient died without evidence 
of disease. The 5-year OS and DFS were both 90% (Figure 1A and 1B).
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Table 1. Patients’ and tumor characteristics for all patients (n = 77) and for patients with high- and 
intermediate-grade, resected osteosarcoma of the head and neck, age < 75 years according to treatment 
with (neo-)adjuvant chemotherapy.
All patients High- and intermediate-grade, resected 
osteosarcoma of the head and neck, age <75 y
No. of patients = 77
 
No. of patients  
(%)
Chemotherapy
 
No. of patients  = 29 
No. of patients (%)
No chemotherapy
 
No. of patients = 21  
No. of patients (%)
Sex
     Male
     Female 
36 (47)
41 (53)
16 (55)
13 (45)
10 (48)
11 (52)
Age, y
     Median (range) 46 (16-95) 41 (16-74) 57 (19-75)
Tumor site
     Maxilla
     Mandible
     Paranasal sinuses
     Skull bone
     Skull base 
     Orbital bone 
     Ethmoid bone
     Other 
24 (31)
32 (42)
7 (9)
4 (5)
2 (3)
3 (4)
2 (3)
3 (4)
8 (28)
11 (38)
4 (14)
2 (7)
0
3 (10)
0
1 (3)
5 (24)
11 (52)
0
2 (10)
1 (5)
0
0
2 (10)
Osteosarcoma subtype 
     Conventional
     Chondroblastic
     Osteoblastic 
     Sclerosing
     Fibroblastic 
51 (66)
11 (14)
6 (8)
2 (3)
7 (9)
13 (45)
7(24)
6(21)
2 (7)
1 (3)
11 (52)
6 (29)
2 (10)
0
2 (10)
Grade 
     Low 
     Intermediate
     High
     Unknown
11 (14)
6 (8)
58 (75)
2 (3)
0
3 (10)
26 (90)
0
0
3 (14)
18 (86)
0
Resection margins
    Complete, no. (%)
    Incomplete, no.(%)
    No surgery, no. (%) 
38 (49)
32 (42)
7 (9)
13 (45)
16 (55)
10 (48)
11(52)
Median follow up time in mo 
(range)
 
34 ( 0-223)
 
30 ( 4–181)
 
44 ( 1–223)
Local recurrence 
Local recurrence and 
      distant metastases 
Distant metastases
14
7
4
2  
1 
 
2 
8 
5 
 
1
Deaths 35 8 13
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a)
b)
Figure 1. (a) Overall survival estimation stratified by the differentiation grade of the tumor of all patients 
(log rank p =.023). Two patients were left out of this figure because of an unknown differentiation grade. 
(b) Disease-free survival estimation stratified by the differentiation grade of the tumor of resected patients 
(log rank p =.029). Nine patients were left out of this figure, 2 patients because of an unknown differentiation 
grade, and 7 patients for not having surgery, and, thus, not being disease-free at any time.
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High- or intermediate-grade osteosarcoma of the head and neck 
Sixty-four patients had high- or intermediate-grade osteosarcoma of the head and neck. 
Fourteen patients were excluded from further analysis for the effect of chemotherapy 
because of their age (75 years or older) or because no surgical resection was performed. The 
characteristics of the remaining 50 patients, are displayed in Table 1 according to treatment 
with (neo-) adjuvant chemotherapy. Treatment characteristics are shown in Figure 2.
All patients 
(n = 77) 
Surgery 
(n = 70) 
No surgery 
(n = 7)
Low grade 
(n = 11)
High and 
intermediate 
grade 
(n = 57) 
Age ≥ 75 
(n = 7) 
Age < 75 
(n = 50)
Chemotherapy
(n = 29)
No chemotherapy 
(n = 21) 
Radiotherapy
 (n = 6 ) 
No radiotherapy 
(n = 23 ) 
Radiotherapy 
(n = 5)
No radiotherapy 
(n = 16 ) 
No chemotherapy 
(n = 11)
Radiotherapy 
(n = 1)
No radiotherapy 
(n = 10 ) Unknown grade 
(n = 2)
Figure 2. Treatment algorithm for all patients with special notice to patients with high- or intermediate-
grade resected osteosarcoma of the head and neck, aged <75 years. 
Treatment 
A total of 29 patients (58%) received chemotherapy, of whom 12 patients (41%) received 
neoadjuvant, 8 (28%) received adjuvant and 9 (31%) both neoadjuvant and adjuvant 
chemotherapy. The most frequently used chemotherapy consisted of a combination of cisplatin 
and doxorubicin. The median number of cycles of chemotherapy was 4 (range 1 – 6 cycles). 
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After neoadjuvant chemotherapy (n = 21), the resection specimens showed >90% tumor 
necrosis in 5 (24%) patients. Forty-five percent of chemotherapy-treated patients had a 
complete resection versus 48% in patients who did not receive chemotherapy (Table 1). Six 
patients (21%) treated with chemotherapy and 5 patients (24%) not treated with chemotherapy 
received radiotherapy (Figure 2). 
Recurrent disease and survival 
The numbers of local recurrences and/or distant metastases in patients with a high- or 
intermediate-grade osteosarcoma of the head and neck and aged <75 years are shown in 
Table 1. After a median follow-up time of 30 months (range, 4–181 months) and 44 (range 
1-223 months) respectively, 8 patients in the chemotherapy treated and 13 patients in the non-
chemotherapy treated group had died. The 5-year OS was 66% versus 51% in the chemotherapy 
versus non-chemotherapy treated patients, respectively, and the respective 5-year DFS was 
67% versus 33%. 
Prognostic factors 
Univariate analysis
In univariate analyses, surgical resected patients with a high- or intermediate-grade 
osteosarcoma of the head and neck, aged <75 years, and not treated with (neo-)adjuvant 
chemotherapy had a significantly worse DFS (HR = 2.50; 95% CI 1.09–5.71; p= .030) and higher 
risk of local recurrence (HR = 3.78; 95% CI 1.35-10.62;  p= .012). There was no significant 
difference in OS (HR = 1.60; 95% CI 0.66–3.86; p = .30). Patients with an incomplete resection 
had a significantly worse OS (HR = 2.75; 95 % CI 1.13–6.73; p= .026), DFS (HR = 2.56; 95 % CI 
1.10–5.93 p= .029) and higher risk of local recurrence (HR = 3.66; 95% CI 1.29–10.38; p= .015). 
Male sex, radiotherapy and age were not significant prognostic factors in a univariate analysis 
for OS, DFS and LRFI (Table 2).
Multivariable analysis
In a multivariable analysis, surgical resected patients with a high- or intermediate-grade 
osteosarcoma of the head and neck, aged < 75 years, and not treated with (neo-)adjuvant 
chemotherapy had a significantly higher risk of a local recurrence, when adjusted for age and 
resection margins (HR = 3.66; 95 % CI 1.21-11.08; p = .022). Chemotherapy had no significant 
impact on OS and DFS.
Patients with an incomplete surgical resection had a significant worse OS (HR = 3.72; 95 % 
CI 1.43–9.69; p= .007), DFS (HR = 3.10; 95 % CI 1.28–7.55; p =.013) and higher risk of local 
recurrence (HR = 3.72; 95 % CI 1.28–10.79; p = .016), when adjusted for age and chemotherapy 
(table 2). 
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Table 2. Univariate and multivariable analysis for high- and intermediate-grade, resected osteosarcoma 
of the head and neck, aged < 75 years, for overall survival, disease-free survival and local recurrence-free 
interval.
High- + intermediate-
grade, resected 
patients, age <75 
OS
HR (95% CI) 
p 
value
DFS
HR (95% CI) 
p 
value
LFRI
HR (95% CI) 
p 
value
Univariate analysis 
(No. of patients = 50)
Age, y 1.02 (1.00 - 1.05) .072 1.02 (0.99 - 1.04) .16 1.01 (0.98 – 1.04) .49
Incomplete resection 2.75 (1.13 – 6.73) .026 2.56 (1.10 – 5.93) .029 3.66 (1.29 – 10.38) .015
No chemotherapy 1.60 (0.66 – 3.86) .30 2.50 (1.09 – 5.71) .030 3.78 (1.35 – 10.62) .012 
Male sex 0.83 (0.34 – 2.00) .67 0.88 (0.39 – 1.99) .76 1.27 (0.50 - 3.24) .62
Radiotherapy 1.76 (0.64 – 4.89) .28 1.70 (0.66 – 4.36) .27 1.68 (0.59 – 4.74) .33 
Multivariable analysis 
(No. of patients =  50 )
 
Age, y
Incomplete resection
No chemotherapy 
1.03 (1.00 – 1.06)
3.72 (1.43 – 9.69)
1.06 ( 0.40 – 2.77)
.03
.007
.91 
1.02 (0.99 – 1.04) 
3.10 (1.28 – 7.55)
2.10 ( 0.85 – 5.18) 
.23
.013
.11 
1.00 (0.97 – 1.03) 
3.72 (1.28 – 10.79)
3.66 ( 1.21 – 11.08)
.87
.016 
.022
Abbreviations: OS, overall survival, HR, hazard ratio;. 95% CI, 95 % confidence interval; DFS, disease-free 
survival; LRFI, local recurrence-free interval. 
In a univariate analysis there was an indication for age as a prognostic factor for OS (p= .072), 
in a multivariable analysis, age actually was a significant prognostic factor for OS (HR = 1.03; 
95 % CI 1.00–1.06; p = 0.03), but not for DFS and LRFI (Table 2). 
OS, DFS and LFRI for patients according to both chemotherapy and resection margins are 
shown in Figure 3A to 3C. Figure 3C gives the probability of local recurrence in the absence of 
the competing risk of death.
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Figure 3. 
(a)  Overall survival estimation for high- and intermediate-grade, resected osteosarcoma of the head 
and neck aged < 75 years according to both resection margins and (neo-)adjuvant chemotherapy 
(log rank p = .036). 
(b)  Disease-free survival estimation for high- and intermediate-grade resected osteosarcoma of the 
head and neck aged < 75 years according to both resection margins and (neo-)adjuvant chemotherapy 
(log rank p =.003). 
(c)  Local recurrence-free interval estimation for high- and intermediate-grade resected osteosarcoma of 
the head and neck aged < 75 years according to both resection margins and (neo-)adjuvant chemotherapy 
(log rank p = .003).
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DISCUSSION 
Because of the rarity of OSHN, conflicting results of in general small case series, and the 
lack of clinical studies, the role of chemotherapy in the treatment of patients with OSHN is a 
continuous subject for debate. We performed one of the largest case studies so far, including 
data of treatment of all individual patients and showed that patients aged <75 years with high 
or intermediate-grade resected osteosarcoma of the head and neck and treated with (neo-)
adjuvant chemotherapy had a significant smaller risk on local recurrence in univariate and 
multivariable analyses, when adjusting for age and resection margins. Although this effect 
was not shown for OS and DFS in a multivariable analysis, this observation has important 
implications. A local recurrence in the head and neck region, in general, causes serious problems 
with hardly any curative options. Often this palliative phase is dominated by (neuropathic) pain, 
speech impairment and swallowing dysfunction with a strongly negative impact on the quality 
of life. Accordingly, prolonged LRFI is considered beneficial for the patient. We showed that this 
could be achieved by administration of (neo-)adjuvant chemotherapy and although we cannot 
present toxicity data of the chemotherapy given, our results suggest that the use of (neo-)
adjuvant chemotherapy is an advantage for patients aged younger than 75 years with high- or 
intermediate grade surgically resected osteosarcoma of the head and neck. 
Patients with intermediate-grade osteosarcoma of the head and neck were analyzed together 
with high-grade patients, because the natural course of disease is more in accordance with 
high-grade than with low-grade osteosarcoma of the head and neck. This is shown by our 
own data and by a French cohort of patients with mandibular osteosarcoma (13). Patients with 
low -rade disease were excluded because of the less aggressive natural course of disease. 
Based on expected toxicity, chemotherapy is not considered for patients above a certain age. 
Therefore, only patients younger than 75 years with surgical resections were included for 
univariate and multivariable analysis. 
As far as we know, this is the first report of an effect of chemotherapy on LRFI in osteosarcoma 
of the head and neck. A systematic review of 201 patients reported an OS and DFS benefit for 
chemotherapy treated patients in those with a complete as well an incomplete resection (4). 
An effect of chemotherapy on LRFI was not reported in this study. A recently published, large 
French cohort of 111 mandibular osteosarcomas, in both children and adults, showed improved 
DFS (HR = 2.87; 95% CI 1.10-7.51; p= .025) and metastatic-free survival (HR = 4.40; 95% CI 1.46-
13.28; p= .004) by (neo-)adjuvant chemotherapy, but no effect on OS(13). These results are in 
line with our findings of an HR of 2.50 (95% CI = 1.09–5.71; p= .030) of chemotherapy on DFS 
in a univariate analysis, and no effect on OS. A meta-analysis of 173 patients did not find a 
survival benefit for adjuvant chemotherapy; however, resection margins were not taken into 
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account (11). The Surveillance, Epidemiology, and End Results database in 541 patients with 
osteosarcoma of the jaw did not provide data on chemotherapy (14). 
Patients with low-grade osteosarcoma of the head and neck have a less aggressive natural 
course of disease. This was also observed in our group in which none of the patients developed 
local recurrences or distant metastases and long-term OS and DFS were both 90%. Therefore, 
these findings do not support the use of (neo-)adjuvant chemotherapy in patients with low-
grade osteosarcoma of the head and neck. 
A history of cancer and/or irradiation is a well-recognized risk factor for development of 
osteosarcoma of the head and neck (13). We report a high incidence of previous malignancy 
(33%). Whether this is due to germ line susceptibility and/or external factors remains to be 
explored. We had a high percentage of patients (25%) previously irradiated in the head and neck 
region, which was even more frequent than the reported 15% for mandibular osteosarcomas(13). 
One of the limitations of this study was its retrospective design. Although care for osteosarcoma 
of the head and neck is centralized in the 8t centres of the Dutch Head and Neck Society, 
heterogeneity exists between the centres. However, a multidisciplinary approach is always 
used in all centres. Because of the small number of patients, only a limited number of events 
occurred and thus only a limited number of prognostic factors could be included in the 
multivariable analysis. The presence of comorbidity was not taken into account.
One of the strong points of this series is the individual base of data collection, studying all 
patients’ medical records. Histological classification was confirmed by either the NCBT or 
pathologists from the NCBT in their affiliated hospitals. Furthermore, we have a long median 
follow-up time, which leads to meaningful clinical observations.
CONCLUSION
Patients with high- and intermediate-grade surgical resected osteosarcoma of the head and 
neck aged younger than 75 years treated with (neo-)adjuvant chemotherapy had significantly 
smaller risk on local recurrence in both univariate and multivariable analyses. Despite the 
limitations of this study, we suggest the use of (neo-)adjuvant chemotherapy in high- or 
intermediate-grade tumors in patients younger than 75 years, irrespective of resection 
margins, because of the large impact on quality of life in case of a local recurrence. 
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SUMMARY
In this thesis, I investigated several rare cancers of the head and neck region. In the first 
parts, two types of salivary gland cancer, salivary duct carcinoma (SDC) (part I) and (mammary 
analogue) secretory carcinoma (SC) (part II) were investigated. In the third part, osteosarcomas 
of the head and neck (OSHN) were subject of study. In these studies the focus was put on 
diagnosis, clinical outcomes, prognostic factors and treatments. 
PART I - salivary duct carcinoma 
A nationwide search for SDC patients was performed, supported by the nationwide network 
and registry of histology and cytopathology in the Netherlands (PALGA) in chapter 2. Endpoints 
of the study were clinical outcomes as defined by overall survival (OS), disease free survival 
(DFS) and distant metastasis free survival (DMFS). Furthermore, prognostic factors for OS and 
DMFS were explored. Importantly, we centrally reviewed all cases to ensure the diagnosis of 
SDC was correct. Moreover, we investigated the expression of the androgen receptor (AR) and 
the human epidermal growth factor receptor 2 (HER2) by means of a tissue micro array (TMA).
 
These efforts led to the inclusion of 177 patients in our series with centrally confirmed SDC. I 
observed a male predilection (75%) and a median age of 65 years at diagnosis. Most tumours 
(82%) occurred in the parotid gland and 36% of patients had a SDC arising from a pleomorphic 
adenoma. Notably, I showed that patients with SDC often present with (extensive) locoregional 
metastasis. Sixty-eight percent of patients had lymph node metastases at first diagnosis. 
Eleven patients (6%) presented with distant metastases. Ninety-two percent of patients 
underwent primary surgery with curative intent. Ninety-one percent of these 162 patients 
received postoperative radiotherapy. 
Univariate analysis showed that male gender, high N-stadium, high total number of tumour 
positive lymph nodes, the lymph node ratio (the number of tumour positive lymph nodes divided 
by the total number of resected lymph nodes) and primary metastatic disease at diagnosis were 
associated with poor OS. Male gender, high T-stadium, high N-stadium, high total number of 
affected lymph nodes and lymph node ratio were associated with poor DMFS. Patients with 
distant metastases at diagnosis and/or patients with missing data (in one or more of the 
assessed characteristics) were not included in the multivariable analysis. In the remaining 
136 SDC patients the absolute number of affected lymph nodes was the only prognostic factor 
for both OS and DMFS in a multivariable Cox regression analysis. More specifically, patients 
with more than three tumour positive lymph nodes had significantly higher hazard ratios as 
compared to patients with no tumour positive lymph nodes. The presence of AR or HER 2 
receptors (in 96% and 29% of patients, respectively) was not prognostic for OS and DMFS. 
Median OS, DFS and DMFS for all stages were estimated at 51, 23 and 26 months, respectively. 
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Recurrent disease, i.e. locoregional recurrence and/or distant metastases after primary 
treatment with curative intent, was observed in 54% of 162 patients. Fourteen percent of 
these 162 patients had a local recurrence, 20% had a regional recurrence, and 47% of patients 
developed distant metastases during our follow up. In patients with local and/or regional 
currencies, 67% also had distant metastasis. 
The median time to distant metastases was 13 months. The most common sites of metastases 
were the lungs, bones and lymph nodes, with a relatively high rate of brain metastases (18%). 
In case of distant metastases, patients received a variety of treatment regimens, some had 
palliative (anti-) hormonal therapy, chemotherapy, targeted therapy or radiotherapy, others 
only received best supportive care.
Treatment options for patients with (incurable) locally advanced or metastatic SDC are limited 
and usually based on case reports or small series. Androgen deprivation therapy (ADT) is 
one of those options, similar to the treatment of AR positive prostate cancer. In chapter 3 
I retrospectively evaluated 35 patients with incurable locally advanced or metastatic SDC 
who were treated with first-line ADT. For comparison, I collected data from 43 patients with 
incurable locally advanced or metastatic SDC treated with best supportive care in the same 
time period. These patients were all part of the 177 patients with SDC described in chapter 
2. Patients on ADT received bicalutamide monotherapy, or an LHRH analogue and low dose 
bicalutamide. Treatment response was evaluated by the Response Evaluation Criteria in Solid 
Tumours (RECIST) version 1.1. I observed a partial response (PR) rate of 18% and a stable 
disease (SD) rate of 32% in the ADT treated SDC patients; thus, the clinical benefit rated 50%. 
In case of clinical benefit, the median PFS was 11 months. For all patients treated with ADT the 
median PFS was 4 months.  
I evaluated baseline patient characteristics in both groups (ADT and best supportive care). The 
median age of ADT patients was 64 years versus 68 years in the best supportive care group, 86% 
percent of ADT patients was male, versus 81% in the best supportive care group. All patients 
in the ADT group had AR expression, versus 81% in the best supportive care group (17% had 
an unknown AR status, 5% had a negative AR). Patients receiving ADT had significantly longer 
OS than 43 patients treated with best supportive care (median OS of 17 months (95% CI 10-24 
months) versus 5 months (95% CI 1 – 9 months), respectively). To evaluate possible confounders 
I investigated the association between treatment and survival by means of estimating a Cox 
regression model. No confounders were found. I concluded that based on our retrospective 
analysis ADT is a reasonable treatment option in AR positive incurable locally advanced or 
metastatic SDC. 
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Besides the presence of the AR resulting in ADT treatment, HER2, if present, may be a potential 
target for treatment of incurable locally advanced or metastatic SDC in analogy with breast 
cancer treatment. Anecdotal data suggest the benefit of chemotherapy in combination with 
trastuzumab, a humanized monoclonal antibody directed against HER2, in SDC patients(1). 
After the recognition of the success of the addition of pertuzumab to the treatment with 
docetaxel and trastuzumab in metastatic breast cancer (2), nowadays, the first-line treatment 
of patients with HER2 positive metastatic breast cancer is the so-called ‘triple therapy’ with 
docetaxel, trastuzumab and pertuzumab. As patients with SDC may also express HER2 in their 
tumour, we hypothesized that adding pertuzumab to docetaxel and trastuzumab may also be 
beneficial for patients with metastatic HER2 positive SDC.
In chapter 4 we were the first to report on two patients who were treated with the ‘triple therapy’ 
docetaxel plus pertuzumab and trastuzumab. One patient had a lasting partial response during 
this treatment. At time of analysis, this patient has received 21 cycles of treatment during 16 
months after start of treatment. The other patient had stable disease during 8 months before 
developing progressive disease. This patient was then treated with trastuzumab-emtansine 
and had a partial response with decrease of target lesions of 70% for 12 cycles (at time of 
publication). We concluded that dual HER2 blockade and even multiple lines of anti-HER2 
targeted therapy were effective in these two patients with HER2 positive metastasized SDC. 
Furthermore, we concluded that trastuzumab-emtansine (T-DM1) was successful and may 
be of interest after failure of dual HER2 blockade. However, the availability of this treatment 
for such a rare cancer will be challenging. In our two patients, the treatment was received in a 
compassionate use / off-label setting.  
Part II - (mammary analogue) secretory carcinoma
In 2010, a new subtype of salivary gland cancer was discovered, characterized by the presence 
of the ETV6-NTRK3 fusion gene and finally called SC. Although some reports describe the 
clinical characteristics, the course of disease remains to be elucidated. 
In chapter 5, I evaluated 31 patients with ETV6-NTRK3 fusion gene positive SC. I observed that 
58% of tumours were located in the parotid gland, which seems to be lower in AciCC (89%), 
and may be a distinguishing clinical feature. The median age of the patients was 49 years with 
a broad range of 19 – 83 years. Patients reported a prolonged time from start of symptoms to 
diagnosis; in some cases up to 20 years. All patients had T1 or T2 tumours. The estimated 5- 
and 10-year OS rates were similar,  95%; the 5- and 10-year DFS were both 89%. One patient 
developed a local recurrence, which was surgically resected. We did not observe any regional 
or distant metastases during the follow up period (median 49 months). Given the excellent 
survival, the use of adjuvant radiotherapy, especially on the regional lymph nodes, is debatable 
and should be subject to further discussion amongst experts in the field.
CHAPTER 7
110
PART III - Osteosarcoma of the head and neck  
Since the introduction of (neo-) adjuvant chemotherapy for patients with osteosarcomas 
of the extremities, their OS improved dramatically. This is based on the early treatment of 
micrometastases, especially in the lungs, at time of diagnosis. However, the role of (neo-) 
adjuvant chemotherapy for OSHN is still controversial and a continuous matter of debate 
among clinicians because of the lower rate of distant metastases in OSHN. 
I therefore collaborated with the eight HNOCs, in which patients with OSHN were diagnosed 
and treated. We did a retrospective analysis of clinical outcome and prognostic factors of all 
OSHN patients and results are described in chapter 6. I was specifically interested in the effect 
of (neo-) adjuvant chemotherapy on survival. I therefore evaluated 77 patients with OSHN, of 
which 11 had low grade OSHN, 6 had intermediate grade and 58 had high grade OSHN. Most 
tumours (73%) were located in either the mandible or maxilla. Remarkably, 25 patients (33%) 
had a history of a previous malignancy, and 19 patients (25%) of patients had received prior 
radiotherapy to the head and neck region. 
As mentioned before, free resection margins were difficult to achieve; in our series more than 
40% of patients had incomplete resection margins. For comparison, in a review of 13 studies 
with patients with extremity osteosarcoma, 244/1559 (16%) had inadequate resection margins 
(3). Patients with incomplete resection margins had worse OS, DFS and higher risk of local 
recurrence. Fourteen out of 77 patients (18%) had local recurrences, 7 patients had both local 
recurrence and distant metastases, and 4 patients had distant metastases only. The 5-year OS 
of all 77 patients was 55%. Patients with low grade OSHN had, as expected, better OS (5-year 
OS of 90%) than patients with intermediate (5-year OS of 80%) and high grade (5-year OS of 
45%) osteosarcoma. 
As patients with low grade OSHN do not have an indication for (neo-) adjuvant chemotherapy, 
these patients were excluded for analysis on the efficacy for (neo-) adjuvant chemotherapy. 
Also, patients older than 75 years of age were excluded, because the used (neo-) adjuvant 
chemotherapy for osteosarcoma is deemed too toxic for elderly patients. Eventually, fifty 
patients with intermediate or high grade OSHN, aged <75 years, were evaluated for the efficacy 
of (neo-)adjuvant chemotherapy. 
In a multivariable analysis, the patients not treated with (neo-) adjuvant chemotherapy had a 
significantly higher risk of a local recurrence when adjusted for age and resection margins (HR 
= 3.66; 95% CI 51.21–11.08; p =0.022). (Neo-) adjuvant chemotherapy had no significant impact 
on OS and DFS in these analyses. Based on the results of our study and the fact that local 
recurrences in the head and neck region are usually not amenable to local curative options, 
because this may lead to disabling symptoms, such as (neuropathic) pain, speech impairment 
 SUMMARY, GENERAL DISCUSSION AND FUTURE DIRECTIVES 
111
7
and swallowing dysfunction, I suggest to consider the option of (neo-) adjuvant chemotherapy 
for patients with intermediate or high grade OSHN in patients younger than 75 years. 
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GENERAL DISCUSSION AND FUTURE DIRECTIVES 
In the next paragraphs I will discuss specific themes regarding salivary duct carcinoma, 
secretory carcinoma and osteosarcomas of the head and neck. 
PART I - Salivary duct carcinoma 
In this thesis I collected data of 177 SDC patients, which is – to our knowledge – the largest 
series of SDC patients with central pathology review worldwide. Another recent multi-centre 
cohort of SDC patients with central pathology review was collected in Japan encompassing a 
total of 141 patients, again stressing the importance of collaboration in (inter)national networks 
(4). 
Other large cohorts of SDC patients consist of two cohorts from the United states, one 
consisting of 495 SDC patients based on the national cancer database (NCDB), the other of 
228 patients from the Surveillance, Epidemiology and End results database (SEER) (5, 6). 
Unfortunately, in both US publications, no central pathology review was performed, which 
may have led to inclusion of patients with other cancers than SDC, as the diagnosis of SDC is 
notoriously difficult to make. Furthermore, the NCDB and SEER database lack information of 
individual patients, for example details about the use of chemotherapy or the development of 
distant metastases. 
As mentioned before, we constructed TMAs for SDC patients. One of the advantages of TMAs 
is the opportunity to test markers in a rapid, homogenous and cost-effective way. The TMAs 
may be used to initiate research on novel (bio)markers and new treatments, such as targeted 
therapy or immunotherapy. 
In our analysis I investigated the efficacy of ADT in patients with (incurable) locally advanced or 
metastatic SDC. As indicated above, a selection bias may have played a role in the comparison 
of the ADT treated patients with patients treated with best supportive care. However, a recently 
published Japanese prospective phase II trial of AR positive salivary gland cancer (34/36 
patients had SDC) confirmed the efficacy of ADT (leuprorelin acetate subcutaneously 3.75 
mg every 4 weeks and oral bicalutamide 80 mg daily) with a 75% clinical benefit rate, and a 
median PFS of 8.8 months. In this trial the median OS was 30.5 months (7). These data are 
in line with the data we presented in our research (a median PFS of 4 months and a median 
OS of 17 months). Currently, a randomized phase II EORTC trial (ClinicalTrials.gov Identifier: 
NCT01969578) compares chemotherapy versus ADT as first line treatment in AR positive 
salivary gland cancers and the results will provide further insight in the treatment of SDC 
patients.
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Given the results we found of ADT, with a clinical benefit ratio of 50%, future research should 
be aimed at finding mechanisms of (primary) resistance to androgen deprivation therapy. 
These investigations should include the search for the presence of AR-v7 and other splice 
site variants in tumour cells. AR-v7 is a splice site variant of the androgen receptor, which is 
constitutively activated (independent of ligand binding with androgens). AR-v7 is associated 
with resistance to abiraterone and enzalutamide in prostate cancer (8). Alternative splice site 
variants, including AR-v7, were already detected in SDC patients without hormonal treatment 
(9). Elucidating mechanisms of resistance may help selecting patients who most likely will 
benefit from ADT, and thus personalising treatment. Currently, this is work is being carried 
out by the Radboud salivary gland cancer research group together with the laboratory of 
experimental urology. 
SDC has a high risk of recurrence, and median OS is limited. One of the unanswered questions 
in light of the efficacy of ADT in the palliative setting is whether ADT holds promise as adjuvant 
treatment for (high risk) SDC. To further investigate this issue, the Radboud salivary gland 
cancer research group are collaborating with Italian colleagues (dr. Locati and dr. Licitra at the 
Istituto Nazionale dei Tumori in Milan) to expand the number of patients treated with adjuvant 
ADT. 
Cell lines and organoid cultures are essential for translational research purposes. Protocols 
for organoid cultures have been developed for prostate cancers. Due to the similarities of 
prostate cancer and SDC, it is interesting to test these protocols to establish organoid models 
for SDC. Organoid models may enable further research not only of SDC biology, but also of 
novel treatments (10) and they will be established in close collaboration with researchers of the 
laboratory of experimental urology of Radboudumc. 
Similarly, for the use of ADT and organoid cultures, more lessons can be learned from prostate 
cancer. Prostate-specific membrane antigen (PSMA) is expressed in the majority of prostate 
cancers. Primary tumours and distant metastases may be accurately diagnosed with 68-Ga-
PSMA-positron emission tomography/computed tomography (68-Ga-PSMA-PET/CT). PSMA can 
be linked with the beta-emitter Lutetium-177 and is used to treat PSMA-positive metastases 
of prostate cancer. One could question if patients with SDC also show targeting of PSMA, and if 
so, may be candidates for treatment with PSMA-Lutetium therapy. In adenoid cystic carcinoma 
(ACC), another subtype of salivary gland cancer, experimental PSMA-PET-scans already 
showed uptake of PSMA in a metastatic setting (11, 12). Therefore, the department of medical 
oncology of Radboudumc performed, and recently accomplished, a phase II study with PSMA-
PET scans for SDC and ACC patients (13). 
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This is one example that illustrates how important it is to find parallels between common 
cancers and rare cancers.
Regarding HER2-targeted therapies, a prospective phase II trial was performed in Japan. 
Fifty-seven patients with SDC were enrolled and treated with a combination of docetaxel and 
trastuzumab. The objective response rate was 70.2% and the clinical benefit rate (defined as 
the proportion of patients who achieved a CR, PR, or stable disease for 24 weeks or more) was 
84.2%. The median progression free survival was 8.9 months and the median overall survival 
was 39.7 months (14). The results of this trial are encouraging, also in light of the manageable 
toxicity profile. 
In this thesis I explored the possibilities of AR- and HER2-directed therapies. Future research 
should however also include next generation sequencing (NGS) to study actionable mutations 
in SDC patients. In a Japanese study of 151 SDC cases, mutations were identified in PIK3CA 
(18%), but also in H-RAS (16%), BRAF (4%) and AKT (1.5%)(15). Actionable mutations may guide 
the search for novel treatments. 
PART II - (mammary analogue) secretory carcinoma 
SC is a relatively new entity of salivary gland cancers. The presence of the ETV6-NTRK3 
fusion gene is pathognomic for SC. SC is a nice example of how rapidly evolving molecular 
classifications lead to new subtypes of cancers. In contrast to SDC, SC patients have a generally 
good prognosis, as we showed in our cohort of 31 patients with low rates of local recurrences, 
no regional recurrences or distant metastases. One of the questions I discussed in our paper 
was related to this favourable prognosis. Was this related to the use of adjuvant radiotherapy 
that some of these patients received, or caused by the intrinsic biological behaviour of SC? 
If the latter is the case, patients may be overtreated with current treatment strategies (i.e., 
elective radiotherapy of the neck in case of N0 disease) and could be the basis of a change 
in the standard treatment. However, conducting prospective studies regarding the value of 
adjuvant radiotherapy for SC patients will be challenging. The discovery of SC as a distinct 
entity of salivary gland cancer only was in 2010, and it will take time before pathologists are 
familiar with this novel diagnosis. Until then, there will be probably underreporting of SC. It 
will therefore be difficult to collect sufficient (prospective) data given the currently available 
patients cohorts (in total 279 patients in a review in 2017 and additionally our 31 patients). 
A prospectively maintained international registry of patients treated at specialist centres, 
could be the basis for further research. The recently established EURACAN network for the 
organisation of care of patients with rare cancers in Europe, in collaboration with the SPECTA 
platform for biobanking of the European Organisation for Research and Treatment of Cancer 
(EORTC), could be the framework for such international collaborations.
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The presence of the ETV6-NTRK3 fusion gene may reveal the possibility of actionable targeting 
in SC, especially in case of distant metastases. Currently, two drugs are being tested, namely 
entrectinib and larotrectinib. 
In a phase 1/2 study, larotrectinib (a highly selective small molecule inhibitor of the TRK 
kinases) was tested in paediatric and adolescent patients with tumours harbouring NTRK gene 
fusions. Three (20%) of 15 patients with TRK-fusion positive cancers had a complete response, 
11 patients (73%) had a partial response. Thus, 14 out of 15 patients with TRK-fusion positive 
cancers had an objective response (as per RECIST 1.1). The median duration of response was 
not reached as most patients were still on treatment at time of analysis. Tumour regression 
was achieved in the remaining patient, although not enough for meeting the criteria for an 
objective response (16). Entrectinib, an inhibitor of the tyrosine kinases TRKA/B/C, ALK and 
ROS1, was also well tolerated and active against patients with tumours with the specified gene 
fusions(17).  One patient with SC had an impressive partial response (89% decrease in tumour 
burden). 
Although the rate of distant metastases seems to be low in SC patients, TRK inhibitors are a 
promising treatment for SC patients with distant metastases. It is therefore very important to 
distinguish SC patients from other subtypes of salivary gland cancers.
PART III - Osteosarcoma of the head and neck 
In chapter 6 I described one of the largest cohorts of OSHN patients. One of the questions I 
tried to answer is whether there is a role for (neo-) adjuvant chemotherapy in OSHN. Our data 
show that patients treated with (neo-) adjuvant chemotherapy had longer local recurrence 
free interval, however, no significant effect on OS or DFS was demonstrated. The higher age 
of patients with OSHN and the relatively high locoregional relapse rate when compared to 
osteosarcoma of the extremities, suggest that both biological and treatment related factors 
play a role in the outcome of these rare tumours. Although our observations were based on 
retrospective data, the often fatal outcome of a locoregional relapse of OSHN requires an 
optimal strategy to achieve at least a delay in local relapse, we suggest to consider (neo-) 
adjuvant chemotherapy in OSHN patients. A recently published retrospective Chinese study 
of 157 patients with OSHN showed that adjuvant chemotherapy was a significant predictor 
for OS (p = 0.025). No significant predictors were found for DFS (age and histological subtype 
were borderline significant). Only margin status and radiotherapy were significant predictors 
for local recurrence (18). 
Combining international data of OSHN patients in a prospective way would support research on 
the role of (neo-) adjuvant chemotherapy in OSHN patients.
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Finally, for patients with OSHN, in contrary to SDC and SC, the possibilities for targeted therapy 
are limited due to the lack of actionable targets. The role of immunotherapy in OSHN requires 
further investigation.
Research in rare cancers
In this thesis, I investigated several rare cancers of the head and neck. One of the major 
bottlenecks for research in rare cancers is the limited number of patients affected each year. 
To overcome this obstacle, I took several steps to increase the patient population incorporated 
in this thesis. Firstly, the patients of interest were evaluated over a long period of time (25 
years in chapter 2 and 3, 20 years in chapter 5). Secondly, diagnosis, treatment and clinical 
outcomes of patients were investigated in detail by reviewing individual medical records. It was 
therefore possible to characterise these patient populations extensively and detailed. Finally, 
collaboration on a nationwide level was accomplished with the eight HNOCs (of the DHNS) in 
the Netherlands and PALGA. The collaboration with PALGA enabled us to analyse both patient 
and pathology data in a coded-anonymous manner, which is in line with the code of conduct. 
With this approach, I was able to examine relatively large groups of patients with very rare 
cancers, which is one of the major strengths of the research presented in this thesis. 
Another strength of the research described, was the presence of expert pathologists (Dr. U. 
Flucke and Prof dr. P. Slootweg) in our team who have expertise in both head and neck and 
sarcoma pathology. This has been crucial for reviewing the pathology specimens. In future 
research, an expert pathologist should always be involved in pathological review of tumour 
samples of rare cancers ensuring the correct patient population is studied. 
Unfortunately, due to the rarity of the studied cancers, this thesis is primarily based on 
retrospective data, which may raise questions and criticism. This is especially the case for 
chapters 3 and 6, in which I retrospectively compared different treatment regimens for SDC 
and OSHN. Although every effort was taken to rule out bias, it was difficult to precisely assess 
how selection bias may have played a role and has affected the results in these chapters. 
Patients’ factors such as co-morbidity and performance score, which may influence whether 
or not a treatment was given, were hardly available, and therefore not possible to adjust for in 
our analyses. 
To overcome these issues in the future it is essential to translate the current knowledge to 
novel study designs or at least to build prospectively maintained real-world (inter)national 
registries. To achieve this, financial constraints should be dealt with in a collaborative effort, 
supported by new (inter)national policy for rare cancers. With the new general data protection 
regulation act the process of combining data sets of rare cancer patients will prove to be even 
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more challenging and a protocol for a prospectively maintained registry with patients’ consent 
from the beginning might be the preferred way to enable future research. 
Many of the difficulties I encountered during our research, are not specific for performing 
research in rare cancers of the head and neck, but may apply for all types of rare cancers. 
Therefore, in the next few paragraphs, I will elaborate on suggestions to improve research in 
rare cancers. 
In recent years, the understanding of many aspects of cancer biology, such as the molecular, 
genetic and biologic processes, has increased tremendously. However, performing randomized 
clinical trials for patients with rare cancers is very difficult. 
Not occasionally, novel treatments are further explored after a successful observation in a 
phase I setting. This is also the case for rare cancer patients, and the option of expansion 
cohorts in phase I studies helps in getting more insight in a reasonable number of patients in 
a relatively short period of time.
Another promising development is the emergence of basket studies. Basket studies are studies 
with targeted therapy directed at a specific molecular aberration. In this type of study, the 
presence of e.g. an actionable mutation is the most important inclusion criterion, and patients 
with different types of tumours may be included, as long as the specific targetable mutation is 
present. In this manner, patients with rare cancers with specific mutations may benefit from 
new developments and treatments, as exemplified by a basket study with vemurafenib for 
patients with BRAF positive tumours. In this study one SDC patient with a BRAF mutation had 
a complete response (19). 
Although NGS may show interesting actionable targets, the availability of a certain drug, in 
particular in a rare cancer, may still be very troublesome. Therefore, in the Netherlands, 
multiple institutions offer the DRUP (Drug Rediscovery Protocol) study, which may also offer 
possibilities for patients with rare cancers. Next generation DNA sequencing will be performed 
to evaluate the presence of actionable mutations. If actionable mutations are present, and 
an approved drug targeting this mutation is available within DRUP, patients can be treated 
accordingly.
Basket studies may also provide a way to investigate immunotherapy in patients with all 
kinds of rare cancers. A promising initiative is carried out specifically for patients with rare 
cancers. In the United States a national clinical trial with immunotherapy for patients with rare 
cancers was initiated. This so-called DART trial (Dual Anti–CTLA-4 and Anti-PD-1 Blockade 
in Rare Tumours) investigates the combination of nivolumab and ipilumimab in such patients. 
 SUMMARY, GENERAL DISCUSSION AND FUTURE DIRECTIVES 
119
7
The trial is sponsored by the federally funded National Cancer Institute (NCI) and is a major 
breakthrough for patients with rare cancers. This initiative is an excellent example of how 
collaboration in networks will advance the cancer care of patients with rare cancers. 
Another important evolution is the approach of The United States Food and Drug Administration 
(FDA) in the process of granting new treatments. Historically, the gold standard for approval 
of a novel treatment is a randomized controlled trial. However, in May 2017, pembrolizumab, 
a monoclonal antibody directed at the programmed death-1 (PD-1) receptor, was granted 
approval for the treatment of adult and pediatric patients with unresectable or metastatic 
microsatellite instability – high (MSI-H) or mismatch repair deficient (dMMR) solid tumours 
progressing following prior treatment and who have no satisfactory alternative treatment 
options based on five uncontrolled, multi-cohort-, multi-centre clinical trials (20).
Furthermore, this is the first tissue/site-agnostic approval of the FDA (21). This could be 
important for patients with rare cancers, when they have the specific biological characteristic 
needed for treatment with pembroluzimab without the need for a randomized controlled trial. 
Unfortunately, the European Medicines Agency (EMA), did not approve pembrolizumab for this 
indication because of regulatory concerns, and pembrolizumab, therefore, is not available for 
this indication on the European market.  
In the process of the investigation of new treatments, early involvement of the FDA and EMA 
is crucial, to discuss optimal trial design to obtain approval even for rare cancer indications. 
Another new treatment design includes the interest for Bayesian methods. Bayesian methods 
may be used to reduce the uncertainty about a treatment effect size in a randomized clinical 
trial, when only small patient populations are affected by the disease. A relatively simple method 
to implement is the maximisation of trial duration, which may improve statistical power by the 
increasing numbers of events. To implement these new treatment designs, the assistance of a 
dedicated statistician is crucial. 
For further improvements in the field of rare cancers the key word is collaboration. As I have 
shown in this thesis, by working together we combine forces and make it possible to investigate 
relatively large groups of patients. In this thesis, I collaborated on a nationwide level. However, 
collaborating research networks should not stop at the national borders. It is crucial to 
collaborate with international partners and form durable research consortia. In this manner, 
the patient population of interest will be larger which makes it possible to do more research 
and obtain even more valuable conclusions. For example, the World Sarcoma Network has 
done research in this way in very rare sarcoma subtypes (22).
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In Europe, efforts are being made to identify European institutions that are involved in the 
managements of patients with rare cancers in adults. As discussed previously, these institutions 
form the EURACAN network, in which the ambition is to establish guidelines, clinical trials 
and develop research projects with national or international partners for patients with rare 
cancers. Ideally, a combined effort from EURACAN and EORTC will lead to clinical studies in 
expert centres for patients with all kinds of rare cancers.
Biobanks
To enable the use of targeted therapies for patients with rare cancers, it is important to 
assemble biobanks to ensure the availability of tumour tissue for providing the possible 
targets for therapy. In this manner, patient care may be individualized. It would be helpful if 
new possible treatment options for patients are registered and shared across the globe, so 
that we can explore new treatments, even if it concerns small patient populations. The recently 
installed general data protection regulation act may however hamper such initiatives.
Patient empowerment 
Finally, patient empowerment is important in future approaches to research. In the Netherlands, 
patients with salivary gland cancer felt an unmet need of loneliness and lack of reliable 
information. Therefore, in December 2015 the first meeting of patients with salivary gland 
cancers was being held in Nijmegen. In this meeting a patient advocacy group for patients with 
salivary gland cancers was founded. The goals of this patient advocacy group are twofold; on the 
one hand exchange of information on salivary gland cancers, as reliable information is difficult 
to find. On the other hand; raising funds for research. A good example was the organization of 
a benefit diner in the renowned Okura hotel in Amsterdam in September 2016, in which funding 
for further research was generated. This exemplifies the powerful contribution of patients and 
their networks to support research in rare cancers. Another exemplar of patients’ support is 
their input in early review of research grants, as their input is valuable not only in defining the 
most meaningful research questions, but also in the feasibility of patient related aspects of 
clinical research.
In conclusion, this thesis offers more knowledge about the diagnosis, treatment, clinical 
outcome and prognostic factors of patients with several rare cancers of the head and neck, in 
particular SDC, SC and OSHN. Future research should aim to further understand their biology 
and improve clinical outcomes for patients affected by these rare and understudied types of 
cancer. 
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In dit proefschrift heb ik meerdere zeldzame kankers in het hoofd-hals gebied onderzocht. In 
het eerste gedeelte bestudeerde ik twee soorten speekselklierkanker, namelijk het salivary 
duct carcinoom (deel I) en het secretoir carcinoom (deel II). In het derde gedeelte kwamen 
osteosarcomen van het hoofd-hals gebied aan bod. De focus werd gelegd op diagnose, 
klinische uitkomsten, prognostische factoren en behandelingen. 
Deel I – Salivary duct carcinoom 
Een salivary duct carcinoom is een maligne tumor die uitgaat van speekselafvoergangcellen 
en vormt een bijzondere groep omdat het gelijkenissen vertoont met borstkanker en 
prostaatkanker. Meestal worden mannen van middelbare leeftijd hierdoor getroffen. Het staat 
bekend als een agressief type speekselklierkanker. 
In hoofdstuk 2 werd een landelijke zoekvraag naar salivary duct carcinoom patiënten opgezet 
met behulp van het Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief (PALGA). De 
eindpunten van deze studie waren overleving, ziektevrije-overleving en afstandsmetastase-vrije 
overleving. Daarnaast werden prognostische factoren voor overleving en afstandsmetastase-
vrije overleving onderzocht. Alle tumoren ondergingen een centrale revisie door de patholoog, 
om te garanderen dat de diagnose van salivary duct carcinoom juist was. 
Verder onderzochten we de aanwezigheid van de androgeen receptor (AR) en de humane 
epidermale groeifactor receptor 2 (HER2) met behulp van een ‘tissue micro array’ (TMA). 
Een TMA is een methode waarbij van veel verschillende tumoren kleine stukjes weefsel 
samengevoegd worden op één parafine blokje om zo sneller bepaalde weefselkenmerken te 
kunnen bestuderen. 
Uiteindelijk leidde dit tot de inclusie van 177 patiënten in onze serie met een centraal bevestigd 
salivary duct carcinoom. In onze serie was 75% van de patiënten man, en de mediane leeftijd bij 
diagnose was 65 jaar. De meeste tumoren (82%) waren gelokaliseerd in de parotis speekselklier, 
36% van de patiënten had een salivary duct carcinoom die ontstaan was uit een pleiomorf 
adenoom. Opvallend was dat patiënten met een salivary duct carcinoom zich vaak presenteren 
met (uitgebreide) locoregionale metastasering. Achtenzestig procent van de patiënten had 
lymfekliermetastasen bij eerste diagnose van salivary duct carcinoom. Elf patiënten (6%) 
presenteerden zich met metastasen op afstand; 92% van de patiënten ondergingen een 
operatie met curatieve intentie en 91% daarvan kregen ook postoperatieve radiotherapie. 
Univariate analyse liet zien dat het mannelijk geslacht, een hoog N-stadium, een hoog totaal 
aantal tumor positieve lymfeklieren, de lymfeklier ratio (het aantal tumor positieve lymfeklieren 
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gedeeld door het totaal aantal verwijderde lymfeklieren) en primair gemetastaseerde ziekte bij 
diagnose geassocieerd waren met een slechte overleving. Het mannelijk geslacht, een hoog 
T-stadium, hoog N-stadium, hoog totaal aantal tumor positieve lymfeklieren en de lymfeklier 
ratio waren geassocieerd met een slechte afstandsmetastase-vrije overleving.
Patiënten met gemetastaseerde ziekte bij diagnose en/of patiënten met ontbrekende 
gegevens (in een of meerdere van de onderzochte karakteristieken) werden niet geïncludeerd 
in de multivariabele analyse. In de overgebleven 136 salivary duct carcinoom patiënten was 
het absolute aantal van aangetaste lymfeklieren de enige prognostische factor voor zowel 
overleving als afstandsmetastase-vrije overleving in een multivariabele Cox regressie analyse. 
Patiënten met meer dan drie tumor positieve lymfeklieren hadden een significant hogere 
hazard ratio (= kans) op overlijden in vergelijking met patiënten die geen tumor positieve 
lymfeklieren hadden. Ten opzichte van patiënten die geen tumor positieve lymfeklieren hadden 
(HR =1), hadden patiënten met 3-15 tumor positieve lymfeklieren een hazard ratio van 2.17 
[95% betrouwbaarheidsinterval 1.09 – 4.32]; voor patiënten met meer dan 15 tumor positieve 
lymfeklieren was de hazard ratio 3.96 [95% betrouwbaarheidsinterval 1.84 – 8.55].
De mediane overleving, ziektevrije-overleving en afstandsmetastase-vrije overleving voor alle 
patiënten waren respectievelijk 51, 23 en 26 maanden. De aanwezigheid van de AR of HER2 
receptor (in 96% en 29% van de patiënten, respectievelijk) was geen prognostische factor voor 
overleving en afstandsmetastase-vrije overleving. 
Na initiële behandeling met curatieve intentie is er in 54% van de 162 patiënten sprake 
van terugkeer van ziekte, dat wil zeggen locoregionale ziekte en/of metastasen op afstand. 
Veertien procent van deze 162 patiënten hadden een lokaal recidief, 20% had een regionaal 
recidief, en 47% van de patiënten ontwikkelden metastasen op afstand tijdens de follow up 
periode. In 67% van de patiënten met lokale of regionale terugkeer van ziekte was er ook 
sprake van afstandsmetastasen. De mediane tijd tot afstandsmetastasen was 13 maanden. 
De meest voorkomende lokalisaties van metastasen waren de longen, botten en lymfeklieren; 
tevens was er een relatief hoog aantal patiënten met hersenmetastasen (18%). Indien er 
sprake was van afstandsmetastasen, was er een grote variatie in behandeling die patiënten 
kregen, sommigen kregen (anti)hormonale therapie, chemotherapie, doelgerichte therapie of 
radiotherapie, anderen kregen alleen ondersteunende therapie (=best supportive care). 
Behandelopties voor patiënten met (ongeneeslijk) lokaal gevorderde of gemetastaseerd 
salivary duct carcinoom zijn beperkt en meestal gebaseerd op case reports of kleine series. 
Androgeen deprivatie therapie is een van die opties, gelijk aan de behandeling van AR positief 
prostaatkanker. 
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In hoofdstuk 3 zijn 35 patiënten beschreven van wie ik de uitkomsten van hun behandeling 
retrospectief heb bestudeerd. Deze patiënten hadden een ongeneeslijk lokaal gevorderd of 
gemetastaseerd salivary duct carcinoom en zijn allen behandeld geweest met eerstelijns 
androgeen deprivatie therapie. Om de uitkomsten te kunnen vergelijken verzamelde ik ook de 
gegevens van 43 patiënten met ongeneeslijk lokaal gevorderd of gemetastaseerd salivary duct 
carcinoom die best supportive care kregen in dezelfde tijdsperiode. Patiënten met androgeen 
deprivatie therapie ontvingen bicalutamide monotherapie, of een LHRH analoog in combinatie 
met een lage dosis bicalutamide. De respons van behandeling werd geëvalueerd met de 
“Response Evaluation Criteria in Solid Tumours” (RECIST) versie 1.1. In deze 35 patiënten 
bereikte 18% een partiële respons en 32% een stabiele ziekte met androgeen deprivatie 
therapie. Bij deze 50% van de patiënten die een partiele response of stabiele ziekte hadden, 
was de mediane progressie vrije overleving 11 maanden. Voor alle patiënten behandeld met 
androgeen deprivatie therapie was de mediane progressie vrije overleving 4 maanden. 
Voor het beoordelen van de vergelijkbaarheid van de patiënten die androgeen deprivatie 
therapie of best supportive care kregen, was het van belang om de karakteristieken van beide 
patiëntengroepen te vergelijken. De mediane leeftijd in de androgeen deprivatie therapie groep 
was 64 jaar versus 68 jaar in de best supportive care groep, 86% van de androgeen deprivatie 
therapie patiënten was man, versus 81% in de best supportive care groep. Alle tumoren van 
de patiënten in de androgeen deprivatie therapie groep hadden AR expressie, terwijl dat in 
81% van de best supportive care groep het geval was. Patiënten die behandeld werden met 
androgeen deprivatie therapie hadden een significant langere overleving dan de patiënten 
die met best supportive care behandeld werden: mediane overleving van 17 maanden (95% 
betrouwbaarheidsinterval 10 – 24 maanden) versus 5 maanden (95% betrouwbaarheidsinterval 
1 – 9 maanden). Bij een Cox regressie model analyse werden er geen factoren gevonden die 
de resultaten mogelijk zouden kunnen verstoren. Op basis van deze retrospectieve studie 
concludeerden we dat androgeen deprivatie therapie een te overwegen behandeloptie is in AR 
positief ongeneeslijk lokaal gevorderd of gemetastaseerd salivary duct carcinoom. 
Naast de aanwezigheid van de AR die tot androgeen deprivatie therapie behandeling kan leiden, 
kan HER2 naar analogie van de behandeling van borstkanker een potentieel aangrijpingspunt 
zijn voor de behandeling van een ongeneeslijk lokaal gevorderd of gemetastaseerd salivary duct 
carcinoom. In Japan is recent een prospectieve fase II onderzoek uitgevoerd. Zevenenvijftig 
patiënten met een salivary duct carcinoom werden behandeld met een combinatie van 
trastuzumab en docetaxel. Het objectieve respons percentage was 70.2%, de mediane 
progressie vrije overleving was 8.9 maanden en de mediane overleving was 39.7 maanden. De 
resultaten van deze trial zijn bemoedigend, ook omdat de bijwerkingen acceptabel lijken te zijn 
(1). 
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Na de ontdekking van het succes van het toevoegen van pertuzumab aan de behandeling met 
trastuzumab en docetaxel in gemetastaseerd mammacarcinoom(2), is de eerstelijnsbehandeling 
voor patiënten met HER2 positief gemetastaseerd mammacarcinoom de zogenaamde ‘triple’ 
therapie met trastuzumab, pertuzumab en docetaxel, met een aanzienlijke winst in overleving 
ten opzichte van trastuzumab en docetaxel. Aangezien patiënten met salivary duct carcinoom 
ook HER2 tot expressie kunnen brengen in hun tumor, zou het toevoegen van pertuzumab aan 
de behandeling met trastuzumab en docetaxel wellicht ook in het voordeel van patiënten met 
gemetastaseerd salivary duct carcinoom kunnen zijn. 
In hoofdstuk 4 deden we als eerste verslag van twee patiënten die behandeld werden met de 
‘triple’ behandeling trastuzumab, pertuzumab en docetaxel. Een patiënt had een aanhoudende 
partiële respons gedurende deze behandeling. Op moment van analyseren, had deze patiënt 
21 cycli van de behandeling ontvangen gedurende 16 maanden na start van de behandeling. 
De andere patiënt had 8 maanden lang stabiele ziekte voordat zij progressieve ziekte 
ontwikkelde. Deze patiënt werd vervolgens behandeld met trastuzumab-emtansine (T-DM1) 
en had hierbij een partiële respons met een afname van 70% na 12 cycli (op moment van 
publicatie). We concludeerden dat dubbele HER2 blokkade en zelfs meerdere behandellijnen 
met HER2-doelgerichte therapie effectief waren in deze twee patiënten met een HER2 positief 
gemetastaseerd salivary duct carcinoom. Tevens concludeerden wij dat T-DM1 ook succesvol 
was, en een mogelijke optie is na falen van dubbele HER2 blokkade. Echter, de beschikbaarheid 
van deze behandeling voor een zeldzame kanker is een uitdaging. In onze twee gevallen werd 
de behandeling gegeven op basis van een ‘compassionate use’ gebruik. 
Deel II – Secretoir carcinoom 
In 2010 werd een nieuw subtype speekselklierkanker ontdekt, welke gekarakteriseerd wordt 
door de aanwezigheid van het ETV6-NTRK3 fusie gen. Uiteindelijk werd deze variant secretoir 
carcinoom genoemd. Het bijzondere aan het secretoir carcinoom is dat het niet alleen in de 
speekselklieren kan optreden, maar ook in andere delen van het lichaam, zoals bijvoorbeeld de 
borst. Er wordt dan hetzelfde fusiegen aangetoond (ETV6-NTRK3). Alhoewel sommige studies 
de klinische karakteristieken beschrijven, moet het beloop van de ziekte nog opgehelderd 
worden. 
In hoofdstuk 5 evalueerde ik 31 patiënten met een ETV6-NTRK3 fusie gen positief secretoir 
carcinoom om meer informatie te krijgen over de patiënt kenmerken en de klinische 
uitkomsten bij deze nieuw ontdekte speekselklierkanker waar nog relatief weinig over bekend 
was. We vonden dat 58% van de tumoren in de parotis speekselklier gelokaliseerd waren. Dit is 
lager dan bij het acinic cell carcinoom, waarbij 89% van de tumoren in de parotis speekselklier 
voorkomt. Vóór het ontdekken van het ETV6-NTRK3 fusiegen, werden patiënten met een 
secretoir carcinoom vaak gediagnosticeerd als een acinic cell carcinoom. Het vaker vóórkomen 
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in de kleinere speekselklieren van het secretoir carcinoom kan een mogelijk onderscheidende 
eigenschap zijn ten opzichte van het acinic cel carcinoom. De mediane leeftijd van de patiënten 
was 49 jaar, met een grote spreiding van 19 tot 83 jaar.
Patiënten rapporteerden een lange tijd vanaf symptomen tot diagnose, in sommige gevallen 
tot wel 20 jaar. Alle patiënten hadden bij diagnose T1 of T2 tumoren. De geschatte 5- en 
10-jaars overlevings percentages waren hoog, namelijk 95%; de 5- en 10 jaar ziektevrije-
overleving waren beide 89%. Een patiënt ontwikkelde een lokaal recidief, welke chirurgisch 
behandeld werd. We hebben tijdens de follow up periode (mediaan 49 maanden) geen regionale 
of gemetastaseerde ziekte geobserveerd. Gezien de uitstekende overleving, is de vraag hoe 
noodzakelijk het is om ook de regionale hals lymfeklieren adjuvant te bestralen. De rol van 
adjuvante radiotherapie zal in de toekomst verder bestudeerd moeten worden. 
Deel III – Osteosarcomen van het hoofd-hals gebied 
Het osteosarcoom is een maligne tumor die primair uitgaat van het bot. Het osteosarcoom kan 
in alle botten voorkomen, maar meestal wordt het aangetroffen in één van de extremiteiten van 
vooral adolescenten en jong volwassenen. Het osteosarcoom van het hoofd-halsgebied is nog 
veel zeldzamer en presenteert zich veelal op volwassen en oudere leeftijd. 
Sinds de introductie van (neo-) adjuvante chemotherapie voor patiënten met een osteosarcoom 
van de extremiteiten is de overleving sterk verbeterd. Deze behandeling is gebaseerd op de 
vroege behandeling van micrometastasen, voornamelijk in de longen, die er op moment van 
diagnose kunnen zijn. Echter, de rol van (neo-) adjuvante chemotherapie voor osteosarcomen 
van het hoofd-hals gebied is nog steeds controversieel en onderwerp van discussie onder 
clinici vanwege het lagere aandeel van afstandsmetastasen bij osteosarcomen van het hoofd-
hals gebied. 
Ik heb daarom samengewerkt met acht hoofd-hals centra, waar patiënten met een 
osteosarcoom van het hoofd-hals gebied gediagnosticeerd en behandeld werden. We hebben 
een retrospectieve analyse gedaan naar de klinische uitkomsten en prognostische factoren 
van alle patiënten met een osteosarcoom van het hoofd-hals gebied. De resultaten hiervan 
beschreven we in hoofdstuk 6. We waren met name geïnteresseerd in het effect van (neo-) 
adjuvante chemotherapie op overleving. Daarvoor evalueerde ik 77 patiënten met een 
osteosarcoom van het hoofd-hals gebied, waarvan 11 een laaggradige tumor hadden, 6 een 
intermediair osteosarcoom en waarbij 58 patiënten een hooggradig osteosarcoom hadden. 
De meeste tumoren (73%) kwamen voor in de mandibula (de onderkaak) en maxilla (de 
bovenkaak). Opvallend genoeg waren er 25 patiënten (33%) die in het verleden al een keer een 
andere maligniteit gehad hadden, zoals bijvoorbeeld het (rhabdomyo)sarcoom, retinoblastoom, 
nasofarynxcarcinoom, oropharynxcarcinoom en mammacarcinoom. Het grootste deel (72%) 
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van deze maligniteiten bevond zich in het hoofd-hals gebied. Negentien patiënten (25%) hadden 
in het verleden radiotherapie gehad in het hoofd-hals gebied. 
In een review van 13 studies bij patiënten met een osteosarcoom in een extremiteit, hadden 
244/1559 (16%) van de patiënten niet-radicale of krap-radicale resectieranden (3). Het 
is moeilijker om vrije resectieranden te behalen in het hoofd-halsgebied; in onze serie 
hadden meer dan 40% van de patiënten irradicale resectieranden. Patiënten met irradicale 
resectieranden hadden een slechtere overleving, ziektevrije-overleving en een hoger risico op 
een lokaal recidief. Veertien van 77 (18%) patiënten kregen een lokaal recidief, 7 patiënten 
kregen zowel een lokaal recidief als metastasen op afstand, 4 patiënten kregen alleen 
metastasen op afstand. De 5-jaar overleving van alle 77 patiënten was 55%. Patiënten met 
een laaggradig osteosarcoom van het hoofd-hals gebied hadden, zoals verwacht, een betere 
overleving (5-jaar overleving van 90%) dan patiënten met een intermediaire (5-jaar overleving 
van 80%) en hooggradig (5-jaar overleving van 45%) osteosarcoom. 
Omdat patiënten met een laaggradig osteosarcoom van het hoofd-hals gebied geen indicatie 
hebben voor (neo-) adjuvante chemotherapie, werden deze patiënten geëxcludeerd bij de 
analyse naar de effectiviteit van (neo-) adjuvante chemotherapie. Daarnaast werden ook 
patiënten ouder dan 75 jaar geëxcludeerd, omdat de gebruikte (neo-) adjuvante chemotherapie 
voor osteosarcomen te toxisch bevonden wordt voor oudere patiënten. Uiteindelijk werden er 
vijftig patiënten met een intermediaire of hooggradig osteosarcoom van het hoofd-hals gebied, 
jonger dan 75 jaar geëvalueerd voor de effectiviteit van (neo-) adjuvante chemotherapie. 
In een multivariabele analyse hadden patiënten die niet behandeld werden met (neo-) adjuvante 
chemotherapie een significant hoger risico op een lokaal recidief, gecorrigeerd voor leeftijd en 
resectiegrenzen (hazard ratio = 3.66; 95% betrouwbaarheidsinterval 1.21 – 11.08; p = 0.022). 
(Neo-) adjuvante chemotherapie had geen significante impact op overleving en ziektevrije-
overleving in deze analyses. Lokale recidieven in het hoofd-hals gebied kunnen meestal 
niet meer genezen worden, waarbij dergelijke recidieven kunnen leiden tot invaliderende 
symptomen, zoals (neuropathische) pijn, beperkingen in het spreken en slikdysfunctie. Daarom 
is ons advies, op basis van de resultaten van onze studie, om (neo-) adjuvante chemotherapie 
te overwegen bij patiënten met een intermediair of hooggradig osteosarcoom van het hoofd-
hals gebied bij patiënten jonger dan 75 jaar. 
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been captured and stored on ‘Statistical Package for the Social Sciences’ (SPSS) files. During 
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het fabriceren van de TMA’s, en de uiteindelijke immunohistochemie en FISH-beoordelingen. 
De samenwerking verliep altijd soepel en was voor mij erg leerzaam. 
Ik wil de leden van de manuscriptcommissie; prof. dr. N. Hoogerbrugge, prof. dr. M. Verheij 
en prof. dr. J.L.N. Roodenburg hartelijk danken voor de tijd en moeite om mijn manuscript te 
beoordelen. 
Zoals ik eerder al schreef, was samenwerking een belangrijke factor in het gereedkomen van 
dit proefschrift. Graag wil ik alle mede-auteurs in andere centra, de Nederlandse werkgroep 
voor hoofd hals tumoren (NWHHT), Pathologisch-Anatomisch Landelijk Geautomatiseerd 
Archief (PALGA) en het Nederlands Kanker instituut (NKI) bedanken in hun rol in het tostand 
komen van mijn proefschrift. 
Er zijn meerdere mensen op de afdeling pathologie die ik wil bedanken. Prof. P. Slootweg, 
dank voor het gebruik mogen maken van uw expertise op het gebied van speekselklierkanker. 
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Marc Tomassen, jouw enthousiasme om bij ons project te helpen was ontzettend welkom. 
Zonder jouw hulp weet ik zeker dat het nooit zo soepel gelopen was. Suzanne Kieboom, dank 
voor het maken van de TMA’s. Dank voor de medewerkers van de coupe administratie die 
ervoor gezorgd hebben dat alles vlekkeloos verliep.
Van het laboratorium experimentele urologie wil ik in het bijzonder prof. dr. J. Schalken, 
Tilly Aalders en Gerald Verhaegh benoemen, jullie enthousiasme om samen te werken 
was aanstekelijk. De wereld van prostaatkanker en speekselklierkanker hebben meer 
overeenkomsten dan je op het eerste gezicht zou zeggen. 
Miranda Bel en Lotte ten Thije, het was enorm leerzaam om jullie te begeleiden in jullie 
wetenschappelijke stage. Dank voor jullie inzet. 
Marianne Jonker en Nelly Peer, dank voor jullie onmisbare hulp met de statische vraagstukken. 
Zowel in de villa interne en externe was het altijd erg gezellig. 
Beste arts-onderzoekers (Chantal, Simone, Steve, Kalijn, Harm, Janneke, Annelieke, Wim, 
Maarten, Martine, Mark, Karin (geen arts-onderzoeker maar toch hoor je hier bij), Myrella, 
Marije, Malou, Charlotte, Vicky, Minke, Wouter en Sarah (en nu maar hopen dat ik toch 
niemand vergeten ben!), eerst in de villa interne, en later ook de villa externe /dungeon. Het 
was een feest om met jullie samen te mogen werken. 
Beste Wim, je nam het stokje van me over. Ik vind het fascinerend om te zien met hoeveel 
enthousiasme en tempo jij in de wondere wereld van speekselklierkanker bent gedoken. 
Hopelijk ben ik eerder klaar dan jij. 
Beste Sarah, met veel enthousiasme heb jij de IMPACT studie verder opgepakt. Mooi om te 
zien dat de eerste papers beginnen te komen.
In de villa interne wil ik ook graag de leden van het fase I team, research verpleegkundigen, 
datamanagers, verpleegkundig specialisten, casemanagers en trial coördinatoren bedanken 
voor de gezelligheid. De gezamenlijke uitjes waren leuk. Samen met Wendy Vorstenbosch 
dit organiseren was me een genoegen. Marlies Kuiperij, jaren werkten we samen aan het 
IMPACT project, we waren een goed geoliede machine. Willeke Rutten-Ros, jouw aanstekelijke 
enthousiasme maakt je een onmisbare schakel op de afdeling. Maaike van Mansum, jouw 
deur stond altijd open voor een gezellig praatje. 
Verder wil ik ook alle medisch oncologen, fellows, secretaresses, poli assistenten en afdeling 
E30 bedanken. Anja Houben, je wist altijd wel weer een gaatje voor me te creëren in de drukke 
agenda’s, dank daarvoor. 
DANKWOORD
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Graag wil ik ook mijn collega’s bedanken met wie ik in het kader van het IMPACT project met 
veel plezier heb samengewerkt. 
In Nijmegen wil ik in dit kader onder andere prof. dr. Wim Oyen, prof. dr. Otto Boerman, drs. 
Anne Arens en dr. Erik Aarntzen bedanken voor de prettige samenwerking. Michel de Groot 
en Maichel van Riel wil ik ook bedanken, de planning van de PET-scans had altijd veel voeten 
in de aarde, zonder jullie had dit niet gekund. 
In Amsterdam dank ik onder andere Erik van Helden, prof. dr. Otto Hoekstra, dr. Willemien 
Menke – van der Houven van Oordt en prof. dr. Henk Verheul. 
In Groningen bedank ik onder andere Suzanne van Es, Frederike Bensch, dr. Adriënne 
Brouwers, dr. Andor Glaudemans, dr. Carolien Schröder, dr. Sjoukje Oosting en prof. dr. 
Liesbeth de Vries voor de prettige samenwerking. 
In Rotterdam wil ik onder andere Lindsay Angus en prof. dr. Stefan Sleijfer danken voor de 
korte maar krachtige samenwerking. 
Beste Bregje, ik wil je bedanken voor het ontwerpen van mijn cover en verzorgen van het 
binnenwerk. Ik ben blij dat ik dit aan je uit kon besteden. 
Natuurlijk wil ik mijn collega’s in het Canisius Wilhelmina Ziekenhuis (CWZ) bedanken voor 
de afgelopen jaren. Dank aan alle internisten voor het creëren van een fijn opleidingsklimaat. 
Dank aan alle arts-assistenten, het is een plezier om met jullie samen te mogen werken. De 
vele activiteiten buiten het werk (zoals borrels, diner roulette, en andere activiteiten) boden 
goede afleiding. Natuurlijk kunnen hier de (opleidings)secretaresses en verpleegkundigen niet 
ontbreken. 
Lieve Rianne, lieve tweelingzus, meer dan 30 jaar geleden kwamen wij samen ter wereld. 
Bijzonder dat je ook op deze belangrijke dag naast me staat. Ik ben er trots op hoe jij je eigen 
weg in Amsterdam hebt gevonden. 
Lieve Marleen, ik ben blij dat jij mijn paranimf wil zijn. Menig potje Carcassone speelden wij, 
op soms bijzondere plekken (ik noem bijvoorbeeld het vliegveld in ons tripje naar Malaga), 
helaas win je het net iets te vaak van me. Onze liefde voor eten (en restjes in pannen) hebben 
wij gemeen. 
Lieve Sensa meiden; Anne, Mercedes, Emma, Simone en Anneke. De woensdag was heilig 
en onze vaste eet-avond (meestal kip tandoori). Hoewel wekelijkse meetingen er niet meer 
inzitten, koester ik de herinneringen aan deze tijd. Anne en Mercedes, jullie waren erg 
gezellige roomies, ik zal de vele engeltjes die ik van jullie kreeg niet vergeten, evenals de grap 
met aluminiumfolie. 
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Lieve Karlien en Corine, we leerden elkaar, door omstandigheden, goed kennen in een 
keuzeblok van de bachelor Geneeskunde. Ondanks dat jullie inmiddels uitgewaaid zijn naar 
twee wereldsteden (Amsterdam en Beuningen) is onze vriendschap nog steeds van grote 
waarde voor mij. 
Lieve Loes, Emy, Lenny en Pien, onze vriendschap gaat al vele jaren terug, we groeiden samen 
op en maakten vele mooie tijden mee (zoals onze eerste zelfstandige vakanties (Renesse, 
Lloret de Mar, Sunny Beach, Medulin), uitgaan, handballen en onze eerste zomerbaantje bij 
de Bergen). Onze vriendschap is bijzonder en hoop dat we nog vele jaren zo door mogen gaan. 
Lieve schmucks; Anouk en Sharon, jullie leerde ik kennen tijdens de introductie van de 
studie Geneeskunde, wat een mooie tijden waren dat! Ik heb mooie herinneringen aan onze 
gezamenlijke reisjes. Later kwamen daar Joyce en Femke nog bij. Nu 12 jaar later komen we 
nog regelmatig samen. 
Lieve ino’s; Carolijn, Carlijn, Tessa en Marleen. We zaten samen in de co-groep, dat leverde 
veel mooie momenten door de jaren heen; bijvoorbeeld onze gezamenlijke wijntjes en dansjes, 
weekendjes weg en vakanties. Het duurde even voordat deze uiteindelijke formatie ontstond, 
maar ik zou er niets meer aan willen veranderen.  
Lieve Paulien (Pul), Wulphert (Wul), Vincent (Vinnie), Marije, Bart (Barry) en Marion, ook wel 
bekend als het 5de wiel, het beste samen te vatten als een ‘dolle bedoeling’. Als voorbeelden; de 
gekte in Albufeira na het winnen van de EK finale door het Portugese voetbalteam, menig avond 
in het bowlingbaan, kroeg of casino, nieuwjaarsvieringen en natuurlijk de recente skivakantie. 
Bedankt voor alle gezelligheid.  
Lieve schoonfamilie, Theo, Rina, Lara, Wesley, Pepijn en Hidde. Wat fijn om jullie als 
schoonfamilie te hebben. Erg bijzonder was ons reisje naar New York voor jullie huwelijks 
jubileum. 
Lieve zussen, Lieke, Anneke en Rianne. Het was erg fijn om op te groeien met jullie drie als ‘oudere 
zussen’ (ook al is dat bij Rianne maar 35 minuten). Doordat jullie voor alles ‘gestreden’ hadden, 
was het voor mij gemakkelijk. Gelukkig kon ik ook wat terugdoen door op diplomatieke wijze bij 
papa en mama van alles voor elkaar te krijgen voor ons. Ik koester de herinneringen aan al onze 
vakanties in onze jeugd. Hopelijk kunnen jullie me ooit ‘vergeven’ voor het ‘prei-incident’ in Frankrijk. 
Hoewel we allemaal wat verspreid door het land zijn gaan wonen, ben ik blij met de momenten 
dat we samen zijn. 
DANKWOORD
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Natuurlijk kunnen hier de 2 J’s (Jan Willem en Joris) niet achterblijven. Dank voor jullie humor 
en het herstellen van het ‘evenwicht’ van bijna alleen maar vrouwen in huize Boon. 
Lief nichtje (Julia) en lieve neefjes (David, Lucas en Gijs), jullie vrolijkheid werkt aanstekelijk, 
ik ben trots jullie tante te mogen zijn. 
Lieve oma, ik weet dat je al lang uitkeek naar de dag van mijn promotie. In gedachten is opa 
er ook bij, ik weet zeker dat hij het prachtig gevonden had. Ik bewonder je moed de afgelopen 
jaren. 
Lieve papa en mama, woorden schieten tekort om mijn dank aan jullie uit te spreken. Jullie 
hebben mij altijd gesteund. Niets is te veel, en jullie staan altijd voor me klaar. Ik waardeer dit 
enorm. 
Lieve papa, er is geen twijfel dat ik een echte Boon ben, ik zie veel van jou terug in mezelf. 
Toen ik klein was, riep ik al dat ik dokter wilde worden, net zoals jij. Hoewel ik me hier in de 
puberteit van af probeerde te zetten, ben ik blij dat ik toch op dit pad terecht gekomen ben. Ik 
waardeer je rust en verstandige adviezen die je geeft over allerlei onderwerpen. Gelukkig zijn 
er ook verschillen, zo wissel ik vaker dan een keer per 20 jaar van outfit. 
Lieve mama, je staat altijd voor iedereen klaar. Helpen met verven, vuilnis meenemen en 
wegbrengen naar de ‘belt’, op de katten passen, het is maar een kleine greep uit alles wat 
je voor ons doet. Toen ik zelf nog geen auto kon rijden, was je menigmaal taxi chauffeur naar 
het handballen, discotheek of vriendinnen. Toen ik eenmaal zelf kon rijden mochten wij menig 
maal de ‘Kuga’ lenen, met een beetje geluk kwam je de auto zelfs brengen naar Nijmegen. Ik 
weet dat je altijd weer blij bent als jij je geliefde Kuga weer terug krijgt, want daar rijdt je het 
liefst in. Gelukkig heeft je schoonzoon het rijden ook ontdekt. Dank voor alles! 
Lieve Jorre, we leerden elkaar kennen tijdens de allereerste werkgroep van de studie 
geneeskunde. Al spoedig waren we onafscheidelijk en kon ik je aan mijn ouders introduceren 
(met de retrospectoscoop wellicht toch wat te vroeg). Met behulp van zus Anneke, was onze 
relatie snel een feit. Inmiddels zijn we bijna 12 jaar samen en vele mooie momenten verder, 
hebben we beide de studie geneeskunde voltooid, beide een promotietraject gestart, en nu 
beide in opleiding tot specialist. Je bent mijn steun en toeverlaat, en hebt me in alle momenten 
gesteund waarin ik dat nodig had. Deze dag wordt extra speciaal doordat wij deze samen 
vieren. Ik kijk uit naar alle onbezorgde momenten die we kunnen gaan hebben samen nu onze 
‘boekjes’ eindelijk af zijn. 
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CURRICULUM VITAE
Eline Boon werd geboren op 7 juni 1989 in Boxmeer. In 2007 voltooide zij de middelbare school 
aan het Elzendaal college te Boxmeer en in datzelfde jaar begon zij aan de studie geneeskunde 
aan de Radboud Universiteit in Nijmegen. 
Tijdens de wetenschappelijke stage van de master geneeskunde deed ze onderzoek naar 
osteosarcomen in het hoofd hals gebied, welke uitmondde in een wetenschappelijk artikel. 
Na het behalen van haar artsentitel in 2014 kreeg zij de mogelijkheid voor een promotietraject 
op de afdeling Medische Oncologie in het Radboudumc. Zij deed dit onder leiding van prof. dr. 
Winette van der Graaf, prof. dr. Carla van Herpen en dr. Uta Flucke. Eline bezocht meerdere 
malen internationale congressen van de American Society of Clinical Oncology (ASCO) en de 
European Society for Medical Oncology (ESMO) om haar werk te presenteren. 
Vanaf mei tot en met december 2017 was Eline werkzaam als ANIOS interne geneeskunde in 
het Canisius Wilhelmina ziekenhuis in Nijmegen. Zij werd aangenomen voor de opleiding tot 
internist in de onderwijs- en opleidingsregio Oost-Nederland. Vanaf 1 januari 2018 werkt ze 
als AIOS interne geneeskunde in het Canisius Wilhelmina ziekenhuis in Nijmegen (opleider dr. 
Ton Dofferhoff). 
Eline woont samen met haar vriend Jorre Mertens.  
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